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Radiation therapy for patients with intact cervical cancer is frequently delivered using
primary external beam radiation therapy (EBRT) followed by two fractions of intracavitary
brachytherapy (ICBT). Although the tumor is the primary radiation target, controlling
microscopic disease in the lymph nodes is just as critical to patient treatment outcome. In
patients where gross lymphadenopathy is discovered, an extra EBRT boost course is
delivered between the two ICBT fractions. Since the nodal boost is an addendum to primary
EBRT and ICBT, the prescription and delivery must be performed considering previously
delivered dose. This project aims to address the major issues of this complex process for the
purpose of improving treatment accuracy while increasing dose sparing to the surrounding
normal tissues.
Because external beam boosts to involved lymph nodes are given prior to the
completion of ICBT, assumptions must be made about dose to positive lymph nodes from
v

future implants. The first aim of this project was to quantify differences in nodal dose
contribution between independent ICBT fractions. We retrospectively evaluated differences
in the ICBT dose contribution to positive pelvic nodes for ten patients who had previously
received external beam nodal boost. Our results indicate that the mean dose to the pelvic
nodes differed by up to 1.9 Gy between independent ICBT fractions.
The second aim is to develop and validate a volumetric method for summing dose of
the normal tissues during prescription of nodal boost. The traditional method of dose
summation uses the maximum point dose from each modality, which often only represents
the worst case scenario. However, the worst case is often an exaggeration when highly
conformal therapy methods such as intensity modulated radiation therapy (IMRT) are used.
We used deformable image registration algorithms to volumetrically sum dose for the
bladder and rectum and created a voxel-by-voxel validation method. The mean error in
deformable image registration results of all voxels within the bladder and rectum were 5 and
6 mm, respectively.
Finally, the third aim explored the potential use of proton therapy to reduce normal
tissue dose. A major physical advantage of protons over photons is that protons stop after
delivering dose in the tumor. Although theoretically superior to photons, proton beams are
more sensitive to uncertainties caused by interfractional anatomical variations, and must be
accounted for during treatment planning to ensure complete target coverage. We have
demonstrated a systematic approach to determine population-based anatomical margin
requirements for proton therapy. The observed optimal treatment angles for common iliac
nodes were 90° (left lateral) and 180° (posterior-anterior [PA]) with additional 0.8 cm and
vi

0.9 cm margins, respectively. For external iliac nodes, lateral and PA beams required
additional 0.4 cm and 0.9 cm margins, respectively.
Through this project, we have provided radiation oncologists with additional
information about potential differences in nodal dose between independent ICBT insertions
and volumetric total dose distribution in the bladder and rectum. We have also determined
the margins needed for safe delivery of proton therapy when delivering nodal boosts to
patients with cervical cancer.
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Chapter 1: Introduction
1.1 RADIATION THERAPY FOR CANCER TREATMENT
1.1.1 What is Radiation Therapy?
Ever since x-rays were discovered by Wilhelm Conrad Röntgen in 1895, it did not
take long for it to be adopted for both diagnostic and therapeutic uses. One of the first
reported uses of radiation for therapeutic purposes was by an Austrian surgeon named
Leopold Freund when he noted the disappearance of a mole following x-ray radiation in 1896
(1). Although radiation therapy has advanced tremendously in the past century, the basic
biological principles have remained the same; deliver sufficient ionizing radiation to
malignant cells with the purpose of breaking enough chemical bonds in the malignant cell
DNA to damage it and prevent cell division. However, the challenge in radiation therapy
(RT) is that radiation does not differentiate between malignant and normal healthy cells.
Therefore, advances in RT have been primarily in the direction of minimizing deposition of
radiation to normal cells while maximizing radiation deposition to malignant cells.
1.1.2 Planning and Delivery of Radiation Therapy
Regardless of treatment modality and site, all radiation therapies contain three major
components; simulation, planning, and delivery. For example, in external beam radiation
therapy, patients are first simulated on a computed tomography (CT) scanner. This provides
radiation oncologists volumetric information about location of disease and normal tissue.
Also, the Hounsfield unit (HU) of voxels of a CT scan acquired from a calibrated CT scanner
1

can be converted to electron density, which gives treatment planning systems the capability
of heterogeneous dose calculation (2). CT simulation is followed by treatment planning.
Normal tissues and treatment targets are delineated by the radiation oncologist. Physicists or
dosimetrists then generate treatment plans which satisfy the prescription criteria set by
radiation oncologists while minimizing radiation to the normal tissues. Finally, after the plans
are approved by the radiation oncologists, patients start receiving daily treatment at typically
2 Gy per fraction delivered using a linear accelerator.
One of the potentially major problems in the current RT process is that the simulation
CT scan only represents a snapshot of the patient’s anatomy and the assumption that this
represents the patient through the entire treatment is made. Since most radiation therapy
courses last 6 – 7 weeks, the assumption that patient anatomy remains unchanged through the
entire treatment is naïve. However, the effects of anatomical variation on target dose
coverage have historically been minimal since beam configurations were simplistic and
margins used were generous. With new technologies such as intensity modulated radiation
therapy (IMRT), treatment plans have become more conformal, which leads to increased
sensitivity to anatomical changes.
Uncertainty caused by anatomical variation is just one of many uncertainties present
in radiation therapy. As technologies become more advanced and more conformal delivery
methods are developed, better understanding of uncertainties is essential to minimize the risk
of underdosing the target. Although some uncertainties are universal, such as CT number and
dose calculation, most uncertainties, including anatomical variations, are treatment site
specific. This work focuses on uncertainties in the treatment of cervical cancer, especially in
2

the treatment of lymph nodal boost, with the hope of improving both the treatment planning
and dose delivery process.
1.2 BACKGROUND OF CERVICAL CANCER
1.2.1 Statistics and Pathology
The cervix is the area connecting the lower part of the uterus and upper vagina.
According to the statistics collected by International Agency for Research on Cancer in 2008
(3), cervical cancer is the third most common type of cancer in women worldwide. However,
mortality rates of cervical cancer in the United States and other Western countries have
reduced dramatically because of advanced screening techniques such as Pap smears. The
National Cancer Institute estimates that there were12,170 new cases and 4,220 deaths in the
United States in 2012 (4). Pathology of cervical cancer suggests that more than 75% of all
cervical cancer cases are squamous cell carcinoma with the remaining composed of
adenocarcinoma and undifferentiated neuroendocrine.
1.2.2 Treatment Methods
Surgery, chemotherapy, and radiation therapy may all be incorporated into treatment
of cervical cancer. Cancer characteristics and side effects must be considered by the radiation
oncologists when determining which treatment option best suits the patient. Clinical staging
of invasive cervical cancer are classified using the internationally accepted International
Federation of Gynecology and Obstetrics (FIGO) system (5). Originally created in 1938 with
four major stage groupings, the system has undergone many revisions including the creation
3

of substages, which starting in 1994 distinguishes microinvasion (IA1 and IA2) and cervical
diameter (IB). The system is unique because it is a clinical and not a surgical or radiographic
staging system. Although it is not perfect, FIGO stages correlates with outcome when
classification rules are strictly followed.
Surgery can be most effectively used in early stage cervical cancer cases. In patients
with stage IA1 disease, where the risk of extracervical involvement is low, type I simple
extrafascial hysterectomy can be performed. Type II radical hysterectomy and pelvic lymph
node dissection is generally recommended for stage IA2 and IB1 cervical cancers. For more
advanced cancers, ultra-radical surgical procedures may be performed, although definitive
chemoradiation is generally recommended in these cases.
Radiation can be used to treat cervical cancer at all stages. Early stage cases such as
IA1 and IA2 can be effectively treated with intracavitary brachytherapy alone for patients
who are not operative candidates (6, 7). More advanced cases require external beam radiation
therapy to treat the nodes as well. The debate between RT and surgery has been a heated
topic with original research showing approximately equal 5 year survival rate of 80% for
both treatment modalities (8). However, retrospective studies could be biased since younger
patients in better health tend to opt for surgical methods because RT could potentially lead to
loss of reproductive function and secondary cancers. On the other hand, one prospective
study comparing RT to surgery showed equivalent disease control but a higher rate of grade
2 to 3 complications in patients who received hysterectomy (9). In addition to being used
alone, radiation therapy is often used in combination with surgery. Two recent prospective
studies have shown the benefits of postoperative pelvic radiation therapy for patients with
4

intermediate risk features (10, 11). These randomized trials have shown a 46% reduction in
risk of recurrence and statistically significant improvements in rate of death in patients
receiving postoperative radiation.
In the past 30 years, many researchers have investigated using either sequential or
concurrent chemotherapy in combination with radiation therapy. Although initial results for
neoadjuvant chemotherapy showed improved tumor response, they did not show improved
survival rates (12-16). However, prospective trials published around the year 2000 showed
significant improvement in overall survival, disease-free survival, and local control rates
when cisplatin based chemotherapy was used concurrently with radiation therapy (11, 1720). For example, one of the studies has shown improved 5-year survival rates for patients
with stage IB to IIB disease (79% versus 55%) (18). Because findings in those studies were
so significant, the National Institute of Health made concurrent chemoradiation the standard
of care for patients with locally advanced cervical cancer (21).
1.2.3 Radiation Therapy of Cervical Cancer
The goal of radiation therapy is to deliver sufficient dose to the target without
exceeding normal tissue tolerance. However, in most cases of radiation therapy of cervical
cancer, paracervical sites and regional lymph nodes are part of the treatment target area in
addition to primary tumor. This makes the target irregularly shaped and conformal treatment
planning very difficult. Because of greater than 3 cm interfractional internal organ motion
(22), large treatment planning margins must be used to assure target coverage throughout
entire treatment. However, using large margins often also means that normal tissues adjacent
5

to the target, such as bladder, rectum, sigmoid, and small bowels, are included in the
treatment fields as well. Therefore, if dose is delivered using external beam RT alone,
tolerance of normal tissues will be reached prior to the targets receiving the prescription dose
(23-25). To maintain normal tissue dose below tolerance, intracavitary brachytherapy (ICBT)
is normally given in conjunction with external beam RT. Brachytherapy treatments take full
advantage of the inverse square law, delivering high doses to tissue closest to the source
while sparing normal tissue beyond a few centimeters.
External Beam Radiation Therapy
There are two major functions of external beam radiation therapy (EBRT); to control
microscopic disease and reduce size of primary tumor. EBRT treatment fields must cover the
cervix, paracervical tissues which include the broad ligaments and uterosacral ligaments, and
involved lymphatic nodes. The most common treatment field technique is using four fields
(anterior-posterior [AP] and laterals). Traditionally, this was the best option because this field
setup spared superficial tissue when low energy beams such as Co-60 sources and 6MV
photons were used. Modern linear accelerators can generate greater than 15MV beams which
makes a two field setup using only AP-PA beams also acceptable. Most radiation oncologists
still prefer the traditional four field setup because studies have shown that using four beams
instead of two can reduce dose to the small bowel and rectum (26). Four field box treatments
are often also referred to as 3-dimentional conformal treatment (3D-CRT). Radiation
oncologists are responsible for delineation of uterus, nodes, vagina, cervix, bladder, rectum,
and margins for the fields.
6

In recent years, many institutions have explored the usage of IMRT for women with
cervical cancer (27-35) with the hope of creating better conformal plans for normal tissue
sparing. Unlike 3D-CRT, IMRT uses inverse planning techniques which automatically create
a plan based on series of planner defined constraints. Planning studies so far have shown
decreased bladder, rectum, small bowel, and even bone marrow dose without compromising
target coverage when IMRT is used instead of 3D-CRT (28, 29, 32, 33). Prospective followup studies comparing IMRT and 3D-CRT have also shown less acute and chronic
gastrointestinal (GI) toxicity for patients receiving IMRT (27, 30, 31, 34). Another method of
delivering intensity modulated radiation therapy is by using volumetric modulated arc
therapy (VMAT) (36). Unlike traditional IMRT, which delivers dose in using predefined
fixed angles, VMAT deliver dose using continuous gantry rotation and multileaf collimator
motion with modulated dose rate. A planning study done by Cozzi et al. comparing IMRT to
intensity modulated arc therapy with results showing improved homogeneity and
conformality index with VMAT and decrease in rectum and bladder mean dose (37).
Although all these results appear promising, the studies do not have enough patients and long
follow-up duration to conclude that local control and survival rates are comparable to
traditional 3D-CRT methods. Also, with the exception of the study by Van de Bunt et al.
(35), which have shown anisotropic anatomical variation requiring treatment margin as large
as 2.4 cm, none of the studies have analyzed anatomical variations during a RT course and its
effect on conformal treatment methods. Because of uncertainties related to patient outcomes
using conformal methods and large interfractional anatomical variations, most intact cervical
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cancer patients receiving primary EBRT at The University of Texas MD Anderson Cancer
Center are still treated with 3D-CRT.
Intracavitary Brachytherapy
ICBT is an integral part of radiation therapy for cervical cancer. Its primary function
is to deliver boost dose to the gross tumor by using solid applicators which consists of a
central tube called tandem and two lateral capsules, called ovoids. Figure 1 shows an
example of the classic Fletcher-Suit-Delclos applicator system. There are three major reasons
why the cervix is ideal for being irradiated using ICBT. First, radioactive sources can be
placed in the center (in middle of cervix), above (inside the uterus), and below (inside the
vagina) the tumor. Second, packing can be used in the vagina to push the bladder and rectum
further away from the radioactive sources, which lowers the dose and toxicity to these
organs. Finally, the uterus and vagina are relatively radioresistant and can tolerate doses as
much as 90 Gy without developing radiation related complexities (38). Historically, ICBT
was delivered using Radium-226 (226Ra), which has the average energy of 830 keV and halflife of 1602 years. However, because of the high energy photon released (up to 2.45 MeV),
226

Ra sources require thick shielding. Also, since it is also an alpha emitter, it is extremely

hazardous if the encapsulation holding the radium sulfate powder were to break. An
alternative source to 226Ra is Cesium-137 (137Cs) which is a 662 keV gamma-ray emitting
radioisotope with 30 year half-life. 137Cs is better than 226Ra because it requires less shielding
and is also less hazardous. It overtook 226Ra as the most used source for ICBT in the mid
1970s. Since the introduction of afterloading methods, Iradium-192 (192Ir) has become the
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source of choice for ICBT. 192Ir has average energy of 380 keV and half-life of 74 days. The
lower energy compared to 226Ra and 137Cs makes shielding more convenient and because it
has high specific activity, it has enough activity for high-dose-rate treatments (described in
more detail next paragraph). The only downside of using 192Ir is its short half life. However,
74 days is long compared to the average treatment time and dose rate decreases by less than
2% during treatment.

Figure 1: The Fletcher-Suit-Delclos applicator system which composes of a tandem and two
ovoids. In the picture, one can see different ovoid sizes (mini to large) and
tandems with varying angles (15° to 45°). Different combinations of tandem and
ovoids can be used depending on patient specific anatomical features.
Historically, low-dose-rate (LDR) ICBT was the preferred method of treatment
because it offers greatest radiobiological advantages (39-44). It is a unique situation where
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damage and repair occurs at the same time. When the dose rate is as low as 1 cGy/min (LDR
dose rates are typically between 0.7 to 1 cGy/min), radiosensitivity of cells decrease and the
curved shoulder portion of the cell survival curve becomes straighter. This effect is critical
because as the survival curves become straighter, the survival percentage difference increases
between normal tissues and tumor cells as dose is increased. Dose delivered using LDR has
almost identical biological effect as dose delivered in 2 Gy per fraction using external beams.
One of the downsides of LDR is in order to deliver enough dose to the target at low dose
rates, long delivery times (typically 72 hours), has to be used. The patient must be
hospitalized and immobile through the entire process, making it very uncomfortable and
inconvenient. When ICBT was first performed, manual loading methods were used. The
sources were preloaded into the applicator before it was inserted into the patient in the
operating room. However, to reduce radiation to medical personnel, afterloading systems,
where sources are manually or remotely loaded into the applicator after it has been inserted
into the patient, were developed and used in the clinic. Afterloading systems also have the
advantage of allowing dose distribution optimization based on patient anatomy and
applicator location after insertion.
In the past fifteen years, a new method of delivering ICBT, using high-dose-rate
(HDR) sources (>1Gy/min), has gained popularity around the world (45-56). This technique
uses a computer controlled remote afterloader to precisely move a single 192Ir source with
activity greater than 10 Ci (3.7x1011 Bq) to different spots (dwell positions) in the applicator.
With tremendous precision in timing and location, a single source can be used to replicate
dose distribution of a LDR treatment. Also, when HDR planning is done using CT images,
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the dose distribution can be inversely optimized like IMRT to create more conformal
treatment plans with greater normal tissue sparing. The advantage of using HDR is that the
entire treatment process takes only a few minutes instead of days. This leads to more
convenience for patients and much less radiation exposure to medical personnel. The major
disadvantage of HDR brachytherapy is that the radiation biology aspect is not well
understood. The current method for calculating biological equivalent (BED) dose of HDR
uses the identical linear-quadratic model as EBRT, which does not factor in typical
brachytherapy BED calculation parameters, such as repair time and exposure duration. Also,
there is no standard method for the delivery of dose using HDR. The dose per fraction and
number of fractionations can vary significantly between institutions. The most common
fractionation scheme in the United States is once per week using 6 Gy per fraction concurrent
with primary EBRT. Literature comparing outcome results between HDR and LDR have
showed equal survival rates between the two for small tumors but significantly lower
survival rates for patients with stage IIIB disease when HDR is used (47, 49, 51, 52, 55).
A third brachytherapy dose delivery method named pulsed-dose rate (PDR)
irradiation can also be used for the delivery of ICBT. A 1 Ci (3.7x1010 Bq) 192Ir source is
used instead of a 10 Ci (3.7x1011 Bq) source as in the HDR system. The source leaves the
remote afterloading unit for approximately 15 min per hour to deliver a 50 to 70 cGy “pulse”.
PDR is a great alternative to LDR and HDR because it has some of the advantages of HDR
irradiation while having similar radiobiological effect as LDR treatments (57-59). For
example, the lower dose rate reduces the room shielding requirements compared to HDR.
Also, since the sources are not inside the patient at all times, nurses and visitors can avoid
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exposure to radiation by entering the room when the source is in the safe. Finally, the
applicators used for PDR are identical to LDR and HDR applicators, which facilitate use for
individuals who have familiarity with such applicators. From all the advantages of using
PDR as discussed above, it is the preferred method of delivering ICBT here at MD Anderson
Cancer Center.
The first guidelines for ICBT treatment planning were the Paris and Manchester
methods (60). In an effort to standardize dose prescriptions and distribution, the International
Commission on Radiation Units and Measurements (ICRU) released a report with
recommendations on dose prescription and treatment techniques on ICBT in 1985 (61).
Traditional points used in the Manchester system such as point A (the location where the
uterine artery cross the ureter) and point B (location of obturator lymph nodes) were
redefined. Additional points including bladder, rectal, and pelvic nodes were defined as well.
Figure 2 shows the location of point A, B, bladder, and rectum. Nodal point definitions are
explained in Section 1.2.4.
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Figure 2: Locations of Point A, B, bladder and rectum as defined in ICRU 38. Point A is
defined as the point 2 cm lateral to the central canal of the uterus and 2 cm up
from the external os. Point B is defined as the point crossing the internal OS,
parallel to the tilt of the pelvis, and 5 cm lateral from the midline. Bladder and
rectum points can be identified on the lateral images. The bladder point is
located on the most posterior surface point of the Foley balloon. The rectal point
is located on a line drawn from the midpoint of the ovoids and 5 mm behind the
posterior vaginal wall.
In recent years, with advances in imaging technology, ICBT treatment planning using
volumetric modalities such as CT and magnetic resonance imaging (MRI) have gained
popularity. One of the advantages of using 3-dimentional images such as CT and MRI
instead of radiographs is much better assessment of the dose delivered to target and critical
organs, since organs are visible with varying tissue contrast. Volumetric imaging provides
information about the tumor, which allows anatomy based dose optimization and inverse
planning. Dose delivered to normal tissues such as bladder and rectum can also be
determined more accurately. Studies comparing ICRU organ points, which represent
maximum dose in theory, with actual dose hotspots (D 2cc ) determined using volumetric
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images have shown varying discrepancy (62-64). In response to the increasing popularity of
using CT or MRI during the ICBT process, the gynecology group of the Groupe Européen de
Curiethérapie-European Society for Therapeutic Radiation and Oncology (GEC-ESTRO)
published a set of recommendations for target volume delineation and treatment planning
using 3-dimentional based treatment planning (65).
1.2.4 Boosting Radiation Dose to Positive Nodes
Lymph node involvement is a very important predictor of patient treatment outcome.
Studies have shown that survival rates for patients with positive para-aortic nodes are
approximately half compared to patients without para-aortic involvement with similar disease
stage (66-69). Therefore, it is important to detect nodes positive for metastasis and prescribe
the appropriate treatment course for patients. There are many methods to detect lymph node
involvement. The most sensitive method is surgical with either transperitoneal
lymphadenectomy or laparoscopic lymph node dissection. Although sensitive, surgical
methods are highly invasive and may cause severe complications (70). Non-invasive imaging
techniques such as CT and MRI can also be used to evaluate lymph node involvement. Large
nodes with diameter greater than 1 to 1.5 cm could potentially suggest disease metastases but
using nodal size alone can result in false positives since inflammation could also cause nodal
enlargement. On the contrary, 18F-fluorodeoxyglucose positron emission tomography (FDGPET) imaging, which measures metabolic activity, is very useful for detecting disease
metastasis in the lymph nodes, with a sensitivity of 82% and specificity of 95% reported in
literature (71-75). Kidd et al. found that using FDG-PET imaging for positive node detection
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is comparable to historical data and correlates to patient recurrence and survival outcomes
(76). Their results showed significant correlation between PET detected positive lymph
nodes and prognosis (Fig. 3).

Figure 3: Kaplan-Meier disease-specific survival probability curves separated by (A) FIGO
staging and (B) PET detected nodal involvement. (Kidd, E et al: J Clin Oncol
Vol. 28, 2010: 2108-13. Reprinted with permission. © 2010 American Society
of Clinical Oncology. All rights reserved.)
Although nodal involvement from cervical cancer may occur anywhere along the
lymphatic drainage pathway, cervical cancer most commonly spreads to the external iliac
nodes and common iliac nodes with lower percentage of spread further away from the
primary site (77, 78). Typically, 45 to 50 Gy is adequate to control microscopic disease in the
lymph nodes and delivered as part of the primary EBRT. Guidelines for delineation and field
setup can be found in ICRU Report 38 (61). When nodal involvement is only in the pelvic
region, nodes are included in the primary fields treating the central disease. Four-field 3DCRT setup is used for extended para-aortic fields to reduce dose to small bowel and kidneys.
In addition, recent studies have shown advantages of using IMRT for extended fields to
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further reduce toxicity (32, 34). An example of an extended field EBRT treatment plan with
all nodal regions treated can be seen in Figure 4.

Figure 4: Example of extended field EBRT which includes primary disease, pelvic nodes,
and para-aortic nodes. Two four-field 3D-CRT sets of beams matching at L5
were used.
In patients where gross lymphadenopathy is discovered, nodal regions are typically
boosted to a total dose of 60 to 66 Gy (79). Prescribing dose for nodal boost is not straight
forward. Although radiation oncologists know how much total dose the nodal region needs to
receive, they must take into account dose contributions to the nodes from primary EBRT and
ICBT. Determining dose contribution from primary EBRT is simple. Since it is part of the
treatment planning target, the nodes receive full prescription homogeneous dose. Nodal dose
contribution from ICBT is slightly more difficult to determine. When 2-dimentional
radiographs are used for treatment planning, nodal structures cannot be seen since soft tissue
contrast on x-ray films is minimal. Therefore, bony structures are used to estimate nodal
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locations and dose. ICRU Report 38 recommends using the reference points on the lymphatic
trapezoid of Fletcher, shown in Figure 5. When CT or MRI images are used for ICBT
planning, positive nodal structures can be seen and delineated by radiation oncologists. The
nodal dose contribution from ICBT is commonly described by taking the mean nodal dose of
the entire volume. Because studies have shown strong correlation between longer treatment
time and decrease in disease control (80-82), the optimal time to deliver nodal dose boost is
during the two weeks of ICBT to prevent elongation of overall treatment duration. However,
since nodal boosts are given prior to the second ICBT fraction, radiation oncologists must
make the assumption that both ICBT fractions contribute equal dose to the nodes. Therefore,
the equation used to calculate boost dose to positive nodes is:
𝐸𝑥𝑡𝑒𝑟𝑛𝑎𝑙 𝑁𝑜𝑑𝑎𝑙 𝐵𝑜𝑜𝑠𝑡 = 𝑇𝑜𝑡𝑎𝑙 𝐷𝑜𝑠𝑒 − 𝑃𝑟𝑖𝑚𝑎𝑟𝑦 𝐸𝐵𝑅𝑇 − (𝐼𝐶𝐵𝑇1 × 2)

17

Figure 5: The lymphatic trapezoid of Fletcher as defined by ICRU Report 38 (61). Shows the
method to determining external iliac, common iliac, and para-aortic nodal dose
from x-ray films. The nodal points are based on bony locations since there is no
soft tissue contrast on radiographs.
Pelvic nodal boost are normally boosted with small AP-PA opposing fields. Using
such field setup allows the avoidance of bladder and rectum, and reduce the risk of ureteral
stricture (83). However, any small bowel in the field will receive the full prescribed dose, as
seen in Figure 6b. For the common iliac and para-aortic nodes, multifield 3D-CRT or IMRT
is normally used to spare the anterior small bowel. Example of a para-aortic nodal boost is
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shown in Figure 6a.

Figure 6: Example of beam setup and dose distribution for a patient receiving nodal boost in
both para-aortic (A) and external iliac (B) nodal regions. Para-aortic nodes were
planed and treated with 8-field IMRT while external iliac nodes are treated with
two field AP-PA beams.
1.3 CURRENT OBSTACLES (AND POSSIBLE SOLUTIONS) IN HIGH PRECISION RADIATION
THERAPY OF CERVICAL CANCER
1.3.1 Motivation for this Project
Cervical cancer is one of the few anatomical sites where radiation therapy combines
multiple courses from different modalities for curative intent. As Section 1.2.3 has shown,
this is a complex process requiring external beam radiation therapy and brachytherapy to
strongly complement each other. Although most researchers have focused on improving
primary EBRT and ICBT, one aspect of cervical cancer treatment that has not been a focus of
research is external beam nodal boost. As discussed in Section 1.2.4, disease detection and
treatment in the nodal regions is extremely crucial to patients’ survival probabilities. Even
though not all patients require nodal boosts, the number of patients requiring nodal boost is
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not negligible. Out of the 95 intact cervical cancer patients treated with primary EBRT and
ICBT at MD Anderson in 2011, 46 (51%) received external beam boost to at least one nodal
region. The motivation behind this project is to seek areas of potential improvement in
boosting dose to lymph nodes and provide solutions.
1.3.2 Difficulty in Prescribing Nodal Boost
Because nodal boost dose is delivered prior to the second ICBT fraction, radiation
oncologists must make assumptions about the second ICBT fraction prior to nodal boost dose
prescription. In current practice, radiation oncologists assume that the first and second ICBT
fractions contribute equal dose to the pelvic nodes. However, this assumption might not be
accurate because the purpose of ICBT is to treat the primary tumor. Independent insertions of
applicators can have many variations; tandem length and rotation, ovoid sizes, applicator
locations in the pelvic, and dose distributions are just a few of the examples. In most
situations, radiation oncologists make the attempt to remain as consistent as possible between
the two ICBT fractions. In practice, this is difficult because patient anatomy could change
dramatically between the two insertions. In cases where radiation oncologists suspect the
nodal dose contribution from the second fraction will be lower, often due to shrinkage of
primary tumor, conservative prescriptions methods are used for nodal boost to prevent underdosage. Such practice makes nodal dose prescription subjective and highly dependent on
radiation oncologist experience. However, if variations in nodal dose between independent
ICBT insertions are analyzed in an unbiased patient population, variations can be quantified
and provide radiation oncologist with extra information when prescribing nodal boost dose.
20

Another difficulty in nodal boost dose prescription is caused by the increasing use of
more conformal radiation therapy methods. Organ dose distributions from whole pelvis
IMRT and inverse planning of ICBT are vastly different from 3D-CRT and brachytherapy
dose distributions. Traditionally, understanding the total dose received by the normal organs
such as bladder and rectum has been simple. During primary EBRT, the bladder and rectum
essentially receive full prescription dose. During ICBT, bladder and rectum dose hotspots can
be estimated using ICRU bladder and rectum points. Therefore, maximum dose to each organ
can be estimated by summing the prescription EBRT dose and ICRU point dose from ICBT.
Bladder and rectum dose distributions from conformal radiation therapy methods are much
more heterogeneous. For example, hotpots and coldspots from inverse planned IMRT are
much less predictable because of the large number of beams and leaf segments. Therefore,
using traditional methods to quantify dose received by normal tissues may lead to
inaccuracies. Since the hotspots from EBRT and ICBT might not be at the same location,
traditional dose summation methods only represent the worst case scenario. One solution to
this problem is by using deformable image registration (DIR) methods, which has the
capability to locate locations of matching voxels on different images. Using DIR, dose
summation can be performed volumetrically since the images are matched voxel-by-voxel.
Better understanding of total normal tissue dose such as bladder and rectum is very important
in prescribing nodal boost. Since normal tissue dose tolerances could be the limiting factors
in nodal boost prescription, higher dose could potentially be prescribed when the actual 3D
dose distributions are viewed instead of just the worst case scenario.
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1.3.3 Rethinking How Nodal Boost Dose is Delivered
Currently, external radiation nodal boosts are delivered using photons. Since photon
beams are attenuated exponentially after the build-up region, all tissues along the beam path
receive some radiation. Therefore, regardless of the beam configuration, some normal tissue
will receive a large amount of prescription dose. For example, although the bladder and
rectum are avoided during external iliac nodal boost, as shown in Figure 6b, the small bowel
receive essentially the full prescribed dose. An alternative method of delivering dose is by
using protons. In proton therapy, the beam has finite range and delivers almost all of its
energy at the end of its range (termed the Bragg peak). Clinically, this feature of protons is
extremely advantageous because all organs beyond the distal edge of the beam can be spared.
Contrary to photons, a single PA proton beam can be used to deliver conformal dose to
external iliac nodes. Small bowel will be spared because it lies beyond the distal margin.
However, the advantages of proton therapy are not without a cost. Proton beams are
extremely sensitive to changes in the beam path. Uncertainty related to anatomical changes
need to be considered thoroughly in order to use proton therapy to target the boost volume.
Dosimetric differences caused by interfractional anatomical variations are magnified in nodal
boosts because a very small target is irradiated over a small number of fractions. Variations
in anatomy in the beam path can cause the proton beam edge to shift off the target, resulting
in under-coverage in either the distal or proximal end of the target. In order for protons to be
used in the clinic, adequate distal and proximal margins must be used during proton nodal
boost planning to account for anatomical uncertainties.
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1.4 ABOUT DISSERTATION
1.4.1 Purpose and Hypothesis
The purpose of this project is to improve external beam radiation therapy of
lymphatic nodal boost during a course of cervical cancer treatment by: 1) Quantifying
interfractional uncertainties. 2) Developing and validating dose accumulation tools between
external beam radiation therapy and brachytherapy. 3) Exploring alternative treatment
modalities.
The hypothesis of this project is separated into three parts. First, rigid 2D-3D image
alignment between films and CT images can be used to quantify nodal dose differences from
independent ICBT insertions. Second, deformable image registration can be used to sum
normal tissue dose from EBRT and ICBT. Third, ray-tracing methods can be used to
determine interfractional anatomical variation margin requirements for proton therapy of
nodal boost.
1.4.2 Specific Aims
There are three specific aims to this project, which are used to address the purpose
and validate the hypothesis. The aims are listed below:
1. Quantify variations in pelvic nodal dose due to applicator placement during a
multi-fraction ICBT course.
2. Develop and validate deformable image registration methods for the use of
volumetric summation of bladder and rectum dose from ICBT to an external
beam planning CT image set.
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3. Calculate nodal boost planning margins needed for proton therapy to account
for interfractional anatomical variations.
1.4.3 Organization of Dissertation
This dissertation is separated into five chapters. The first chapter is used to provide
the necessary background information to the issues and problems that are being tackled in
this project. The next three chapters provide details on the methods used to address each
specific aim and their respective results. Extra background relating to the tools and method in
each specific aim are provided in the middle chapters as well. The final chapter is where all
the results are brought together. It is where we look at the big picture and anticipate the
impact of the findings in this project, discuss how results can be implemented in clinical
practice, and identify future work that could be done to improve upon current findings.
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Chapter 2: Variability in Pelvic Nodal Dose between Independent
Intracavitary Brachytherapy Fractions for Treatment of Cervical Cancer
2.1 SPECIFIC AIM 1
Quantify variations in pelvic nodal dose due to applicator placement during a multifraction ICBT course.
2.2 INTRODUCTION
In patients with involved lymph nodes, which are often identified by PET and/or
biopsy, additional radiation following primary pelvic radiation therapy is delivered to bring
the total lymph node dose to 60 – 66 Gy range (79). Because brachytherapy can contribute a
significant dose to pelvic lymph nodes, it needs to be taken into account when determining
the appropriate final boost dose. At MD Anderson, the external beam boost to involved
lymph nodes is given before the completion of ICBT. Therefore, assumptions about the boost
to positive lymph nodes for future implants are made to determine the lymph node boost
dose.
As discussed in Section 1.3.2, in current practice, radiation oncologists assume that
the first and second ICBT fractions contribute equal doses to the pelvic nodes. However, this
assumption might not be accurate since independent insertions of applicators can vary with
respect to many factors: tandem length and rotation, ovoid size, applicator location in the
pelvis, and dose distributions (84-86), which may all contribute to the variation in node
doses. The purpose of this specific aim was to quantify differences in nodal dose between
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independent ICBT fractions due to applicator placement between ICBT fractions.
Correlations between dose variations and external factors such as tandem angle rotation and
applicator system placement were evaluated as well.
2.3 METHODS AND MATERIALS
2.3.1 Patient Cohort
The MD Anderson Cancer Center Institutional Review Board approved this
retrospective study. Ten patients with intact cervical cancer and positive nodes which
required nodal boost were selected for this study. The patients had clinical stage IIA to IIB
cervical cancer and were treated between August 2008 and December 2010. All patients
received primary EBRT delivered in 1.8-Gy fractions to a total dose of 45 Gy. Two fractions
of PDR ICBT were delivered immediately after EBRT at approximately 20-Gy per fraction
prescribed to Point A. Delivery duration for each ICBT fraction was 44 hours, and the two
fractions were spaced 2 weeks apart. ICBT was delivered using Fletcher-Suit-Delclos tandem
and ovoid applicators with ovoid sizes ranging from small (20-mm dia.) to medium (25-mm
dia.). ICBT planning was performed using orthogonal radiographic films obtained after
applicator insertion in the operating room. All patients also had PET-positive pelvic nodes
that were treated with a boost to a mean total dose of 62.1 Gy (range 60 Gy – 66 Gy). All
patients underwent two CT simulations, one before primary EBRT and one before delivery of
the nodal boost. Positive nodes were delineated on the CT scans by the radiation oncologist.
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2.3.2 Aligning ICBT Film Images and 3D Dose to EBRT CT Image Sets
Since CT images at the time of ICBT were not available for all patients, we had to
devise a method to determine spatial correlation between film and CT images and then
transfer the ICBT dose from the film images to the CT images. Figure 7 provides a schematic
of the methodology that was used; the details of which are presented below. Original ICBT
planning for all patients was performed by dosimetrists and approved by radiation
oncologists. AP and lateral films used for planning were obtained in the operating room
immediately after applicator insertion. In this work, original clinical plans were done in the
Plato treatment planning system (TPS) v. 14.3.7 (Nucletron, Netherlands) and replicated
using the Oncentra TPS v. 4.0 (Nucletron, Netherlands) with dwell positions identical to
those in the original clinical plans. Dwell times on the replicated plans were adjusted to
account for differences in the activity of the current radioactive source and the activity of the
source used at the time of treatment. Dose calculations were performed using guidelines
provided by the American Association of Physicists in Medicine Radiation Therapy
Committee Task Group #43 (87, 88). Unlike its predecessor, Plato, the Oncentra TPS allows
calculation of the dose in three-dimensional space, which we calculated using a dose grid of
30 x 30 x 40 cm3 with a voxel size of 2 x 2 x 2 mm3 centered at the internal os. International
Commission on Radiation Units and Measurements (ICRU) point A (left+right), as defined
in Section 1.2.3, was placed on the replicated plans as a method to verify the accuracy of the
replication process. The plans were then exported as DICOM files, which contained DICOM
images of the AP and lateral films along with the DICOM-dose file. Since each patient had
two ICBT fractions, 20 replica treatment plans were done.
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Figure 7: Schematic of the procedure to determine differences in nodal dose between
independent intracavitary brachytherapy (ICBT) fractions. First, films from
ICBT fractions 1 and 2 (ICBT 1 and ICBT 2) were aligned to the computed
tomography (CT) image set from treatment simulation (sim) performed before
delivery of the nodal boost. Specifically, the original ICBT clinical plans were
replicated using an Oncentra treatment planning system with dwell positions
identical to those in the original clinical plans, and dose calculations were
performed using guidelines provided by the American Association of Physicists
in Medicine Radiation Therapy Committee Task Group 43 (87, 88). To permit
alignment of ICBT film images to CT images, digitally reconstructed
radiographs (DRRs) were generated from CT images in the anterior-posterior
(AP) and lateral (Lat) directions. The replicated ICBT films and the DRRs were
then aligned using a published algorithm (89). The alignment result was used to
shift the ICBT dose into the CT coordinate system to obtain shifted doses for
the first and second ICBT fractions, and these doses were imported into a
Pinnacle (PINN) treatment planning system. Finally, differences in dose were
analyzed volumetrically.
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Because we are aware of no commercial tools that can align two-dimensional film
images to three-dimensional CT image sets and can transfer dose from film plans to CT
images, in-house software using MATLAB v. 7.12.0 (The MathWorks, Inc, Natick, MA) was
generated to achieve the desired task. To align ICBT film images to external beam planning
CT images, digitally reconstructed radiographs (DRRs) were first generated from CT images
in the AP and lateral directions. These DRRs were then exported and aligned with their
respective film counterparts. This is possible because although film images are twodimensional, orthogonal films with a common reference point can provide three-dimensional
information. Aligning two sets of orthogonal two-dimensional radiographs can provide
offsets in the x, y, and z directions.
To align the ICBT films and DRRs, rectangular regions with identical dimensions
encompassing the nodal region of interest and surrounding bony anatomy were first drawn on
both the films and DRR image sets to localize the area used for alignment. Global image
registration was not used because it is more critical to align the region closest to the nodes
correctly than to have the entire pelvic and lumbar region aligned reasonably well. Because
contrast on radiographs is greatest between bone and soft tissue, pelvic and lumbar bony
anatomy within the rectangular regions delineated on the films and DRR image sets were
aligned automatically using cross-correlation algorithm developed by Guizar-Sicairos et al.
(89) and modified for this project. The algorithm uses rigid image registration that allows
three degrees of freedom: translation in the AP, SI, and RL axes. Some of the modifications
such as two secondary checks of alignment accuracy were also developed to facilitate use of
the software. The first displays graticules centered at the isocenter on both film and DRR
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images. The second overlays film and DRR images and displays each using 50% visibility or
a checkerboard of alternating images. When auto-alignment results were inadequate or
appeared incorrect, because of either bad image quality or lack of information, secondary
alignment methods were used and results were adjusted manually. Manual alignment also
allowed for rotations, i.e., pitch, yaw, and roll, of the film images to provide more accurate
alignment. An example screen capture of the graphical user interface of the in-house software
is shown in Figure 8.

Figure 8: User interface created in-house using MATLAB for aligning digitally reconstructed
radiographs (DRRs) and film images. Auto-alignment results can be verified
manually by using the graticules and fusion display.
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To validate the accuracy of our automatic image registration algorithm, a reference
DRR image set and eight shifted DRR image sets with known shifts were created from a
single CT image set, as shown in Figure 9. The shifted DRR image sets were created by
shifting the reference DRR isocenter ±2 cm, ±3 cm, and ±4 cm in the RL, AP, and SI
directions, respectively. Large shifts were chosen to test the robustness of the alignment
method. Using our alignment software, shifted DRRs were treated as simulated ICBT film
images and aligned to the reference DRR images. Without any manual intervention, the shifts
calculated by the alignment software were compared to the known shifts of the isocenters.
Differences in shifts were recorded.
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Figure 9: Reference DRR and 4 out of the 8 shifted DRRs used for validation testing of our
rigid alignment algorithm. Only shifts in the LR and SI direction are shown in
figure.
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To link the ICBT three-dimensional dose to external beam planning CT images, we
needed to know the spatial association between the ICBT dose grid, film images, and
external beam planning CT images. The center of the ICBT dose grid is also the planning
isocenter, which was defined at the internal os during treatment planning. Prior to image
registration, the ICBT film images were cropped so that the internal os was at the center of
the image, which made the center of the images and the dose grid identical. Differences in
film and DRR isocenter, obtained from our image registration software, were then used to
calculate the location of the film isocenter on the CT image set. Once we identified the
location of the film isocenter on the CT image sets, the exported DICOM-dose files from
Oncentra were converted to Pinnacle (Philips Medical Systems, Andover, MA) dose format,
rotated and shifted to the correct isocenter location, and imported into Pinnacle using inhouse-developed software tools.
2.3.3 Analyzing Nodal Dose Differences between Independent ICBT Fractions
The Pinnacle TPS is limited in dose-manipulation such as voxel-by-voxel dose
accumulation and cumulative dose-volume histogram analysis. Therefore, to analyze
differences in nodal dose between two independent ICBT fractions, a three-dimensional
binary mask of all the positive nodes and their doses was exported from Pinnacle to be
analyzed using another in-house MATLAB program. Since dose and CT voxel sizes are not
the same, dose grids were then resampled to obtain the same resolution as the CT image set.
With the binary mask and dose having an identical resolution, we were able to extract dose
within the structures of interest to be evaluated or manipulated. Differences in nodal dose
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contribution between the first (ICBT1) and second (ICBT2) insertions in terms of mean dose
and D 90 (the dose received by at least 90% of the volume) were calculated.
Calculating differences in nodal dose between independent ICBT fractions does not
explain the source of the variations. We wanted to quantify and correlate factors that cause
these dose differences. To eliminate differences caused by dose prescription, we calculated
the ratio between the average ICRU point-A doses from the first and second ICBT fractions
and multiplied the dose from the second ICBT fraction by this ratio. This normalized the
dose of the second fraction, such that its dose prescription was identical to that of the first
fraction. After dose normalization, tandem angle and length variations and system location
shifts were analyzed. Tandem angle variations were determined by measuring the separation
in angle between the tandem and midline of the pelvis, as shown in Figure 10. Tandem length
variations were calculated by measuring the length of tandem from the tip to the internal os.
System location variations were determined by comparing the differences in internal os
location within the pelvis on the CT image set between the first and second ICBT fractions in
RL, AP, and SI directions. The total magnitude of system location shift was calculated by
taking the root of the sum of squares in the three directions. Figure 11 shows differences in
isocenter location between the two ICBT fractions. Two-tailed Spearman’s rho correlation
tests were used to determine whether correlations existed between tandem angle, system
location, and variations in nodal dose.
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Figure 10: Tandem angle (θ) was determined by measuring the separation in angle between
the tandem and midline of the pelvis.

35

Figure 11: Differences in system shifts between the first and second intracavitary
brachytherapy fractions. Variation was smallest in the lateral direction, while
most variation occurred in the anterior-posterior direction. Most shifts between
the first and second fractions were in the anterior and inferior direction. Box
graphs show 25th percentile, median, 75th percentile, and outliers for variations
in each axis.
2.4 RESULTS
2.4.1 Validation of Image Registration Algorithm
Validation results of the automatic image registration algorithm used in this study is
shown in Table 1. The mean discrepancies between the calculated and known shifts were
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0.78 mm, 0.8 mm, and 1.14 mm in the RL, AP, and SI directions, respectively. Maximum
discrepancies between the calculated and known shifts were 1.25 mm, 1.88 mm, and 2.5 mm
in the RL, AP, and SI directions, respectively.
Table 1: Results for auto-alignment algorithm. A reference DRR image set was first
generated using isocenter near the center of the pelvis. Shifted-DRR image set
were generated by shifting the isocenter ±2 cm, ±3 cm, ±4 cm in the LR, AP,
and SI directions, respectively.
Shifted-DRR image
set (isocenter shift)
2 cm left
3 cm anterior
4 cm inferior
2 cm left
3 cm anterior
4 cm superior
2 cm left
3 cm posterior
4 cm inferior
2 cm left
3 cm posterior
4 cm superior
2 cm right
3 cm anterior
4 cm inferior
2 cm right
3 cm anterior
4 cm superior
2 cm right
3 cm posterior
4 cm inferior
2 cm right
3 cm posterior
4 cm superior
Mean
Max

Difference (mm)
RL

AP

SI

1.25

1.88

2.11

1.25

1.09

1.33

0.31

0.47

2.50

0.31

0.47

0.16

1.25

0.47

0.94

1.25

0.47

1.72

0.31

0.47

0.23

0.31

1.09

0.16

0.78
1.25

0.80
1.88

1.14
2.50
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2.4.2 Nodal Dose Differences from Independent ICBT Fractions
For analysis of differences in patient nodal dose between the first and second ICBT
fractions, nodes were divided into two regions, distal pelvic and proximal pelvic, with respect
to location of central disease. The distal pelvic region included common iliac lymph nodes,
and the proximal pelvic region contained external, internal, and obturator lymph nodes. Of
the 10 patients, 6 had PET-positive distal and proximal pelvic nodes, 3 had PET-positive
proximal pelvic nodes only, and 1 had PET-positive distal pelvic nodes only. All nine
patients with positive proximal pelvic nodes had bilateral positive nodes. Of the seven
patients with positive distal pelvic nodes, five had multiple positive distal pelvic nodes, and
two had a single positive distal pelvic node. Together, the 10 patients in the study had 20
positive proximal pelvic nodes and 14 positive distal pelvic nodes. Approximate locations of
all nodal centroids, or geometric center, as calculated by Pinnacle TPS are show in Figure 12.
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Figure 12: Approximate centroid locations of all analyzed nodes for all patients displayed on
an atlas computed tomography image. The blue and green spheres represent
nodes in the distal and proximal pelvic regions, respectively.
Differences in nodal dose contributions between the ICBT1 and the ICBT2 are shown
in Figure 13. Positive and negative nodal dose differences between the two ICBT fractions
means higher and lower ICBT dose from the second fraction, respectively. For the proximal
and distal pelvic nodal regions, the mean±1SD (range) differences between the ICBT1 and
39

ICBT2 mean nodal dose were 8.6±85.1 (-134.5 to 192.8) cGy and -46.8±55.3 (-172.7 to
20.0) cGy, respectively. The 10th-percentile, 90th-percentile, and median differences
between ICBT1 and ICBT2 mean nodal dose were -92.8 cGy, 134.1 cGy, and 8.9 cGy,
respectively, in the proximal pelvic region and -143.4 cGy, 14.1 cGy, and -18.86 cGy,
respectively, in the distal pelvic region. Mean differences between ICBT1 and ICBT2 D 90 for
proximal and distal pelvic nodal regions were 5.2±69.8 (-110.6 to 145.2) cGy and -21.9±38.4
(-84.6 to 46.9) cGy, respectively. The 10th-percentile, 90th-percentile, and median
differences between ICBT1 and ICBT2 D 90 were -82.4 cGy, 109.1 cGy, and 0.9 cGy,
respectively, in the proximal pelvic region and -83.9 cGy, 30.3 cGy, and -10.5 cGy,
respectively, in the distal pelvic region.
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Figure 13: Differences between the expected and delivered nodal dose from intracavitary
brachytherapy for the proximal and distal pelvic regions. Box graphs show 25th
percentile, median, 75th percentile, and outliers for both the mean nodal dose
and the dose received by at least 90% of the nodal volume (D90).
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2.4.3 Correlation between Tandem and Applicator Location Variations and Nodal Dose
Difference
Two-tailed Spearman’s rho correlation tests were performed between tandem angle
and length variations, applicator system location variations in the RL, AP, SI directions, total
magnitude of applicator system shift, and normalized nodal dose differences from
independent ICBT fractions. Proximal pelvic node dose was affected by AP and lateral shifts
in applicator placement. Distal pelvic nodes were impacted by tandem angle and total
magnitude of applicator shift. Also, with the exception of one node, anterior shifts increased
pelvic node doses, while posterior shifts decreased node doses. Plots for all significant pairs
are shown in Figure 14.
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Figure 14: Graphs of normalized dose differences for pelvic nodes between the first and
second intracavitary brachytherapy (ICBT) fractions versus applicator changes
between the first and second ICBT fractions for relationships with significant
correlations (p<0.05).
2.5 DISCUSSION
To the best of our knowledge, difference in pelvic nodal dose from different ICBT
fractions has not been explored previously. Results from this work show that the absolute
difference in mean node dose from independent implants can be as high as 1.9 Gy and 1.7 Gy
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in proximal and distal pelvic nodes, respectively. However, only 20 percent of proximal and
21 percent of distal mean nodal dose absolute differences were greater than 1 Gy.
To achieve this study objective, we developed an in-house software with the capacity
to utilize exported DICOM images and dose files from the Oncentra TPS, align the twodimensional film images with CT image sets from EBRT, and import corrected
brachytherapy dose onto the CT image. The results from validation of our auto-alignment
algorithm showed that on average, the registration error was small. In the RL and AP
directions, the average difference was less than 1 mm, while it was slightly more than 1 mm
in the SI direction. The worst registration errors in the RL, AP, and SI directions were 1.25
mm, 1.88 mm, and 2.50 mm, respectively. This is not surprising because registration
accuracies are highly dependent on image resolution and the CT image set used for testing
had 1.2-mm resolution in the RL and AP directions and 2.5-mm resolution in the SI
direction. Therefore, in the worst-case scenario, differences resulted from misalignments is
approximately 1 pixel. Also, although the DRRs were generated from the same CT image set,
there are still differences because shifting isocenter and regenerating DRR images is not
equivalent to shifting the center and cropping the reference DRR images. DRRs are
generated by projecting a point source through the CT image. By shifting the isocenter, we
essentially shifted the point source and generated new images from the new reference point.
Therefore, regenerated DRR images are not identical, especially for pixels that are further
from the isocenter.
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2.5.1 Nodal Dose Variations in the Proximal Pelvic Region
In the proximal pelvic region, the mean difference between the ICRT1 and ICRT2
mean nodal dose was 8.6 cGy, such difference is negligible. This indicates equal probability
for the second ICBT fraction to contribute lesser or greater dose than the first ICBT fraction.
However, the 1SD in dose difference for proximal pelvic nodes was almost 1 Gy with
maximum absolute difference being 1.93 Gy. Spearman’s rho two-tailed tests indicated that
the difference in proximal pelvic nodal dose was significantly correlated with shifts in the
applicator system in the RL and AP directions (p<0.05). This is not unexpected because dose
distribution directly follows the applicator placement and any shifts in the axial plane would
move the distribution either closer to or further from the nodal region of interest. Figure 14a
shows that in general, the contribution to nodal dose from the second ICBT fraction
increased when the applicator system moved anteriorly and decreased when the applicator
system moved posteriorly. This occurred because applicator placement is normally posterior
to the proximal pelvic nodes and if the applicator is moved more anteriorly, the higher-dose
region will be closer to the nodes and cause an increase in nodal dose. Figure 14b shows that
in general, when the applicator system was shifted laterally, dose to the nodes on the side of
the shift increased. Differences in nodal dose are always caused by a combination of factors,
and there are always exceptions to the rule. For example, from Figure 14b, one of the
proximal pelvic nodes on the left side of the patient decreased in dose when the applicator
system is shifted to the left side by 3-mm. However, for the same patient, the system shift
also moved posterior in the second ICBT fraction, by 1.1-cm, thus causing decrease in
proximal pelvic nodal dose.
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Another factor which would result in differences in pelvic node doses between the
first and second ICBT fraction is ovoid size. In theory, changes in ovoid size would result in
dose distribution variations, which potentially can lead to dose changes to the proximal
pelvic nodes. However, in the patient cohort used in this study, only one of the ovoids used in
a single ICBT fraction was medium sized. Since all remaining ovoids were small, no
conclusion can be made about nodal dose differences caused by ovoid size changes.
2.5.2 Nodal Dose Variations in the Distal Pelvic Region
Compared to the proximal pelvic nodes, the distal pelvic nodes had a more negative
mean difference in mean nodal dose (-46.8 cGy) and a smaller 1SD (55.3 cGy). This shows
that the dose contribution to the distal pelvic nodes was almost always lower during the
second ICBT fraction. This could potentially be caused by tumor shrinkage between the first
and second ICBT fractions, necessitating a more conformal dose distribution. Correlation
tests showed that the difference in distal pelvic nodal dose was significantly correlated
(p<0.01) with tandem angle and the total magnitude of the applicator system shift. Plotting
tandem angle versus dose change (Figure 14c), we see that with the exception of one patient,
dose decreased when tandem angle changed during the second ICBT fraction. This is
expected because dose to the distal pelvic nodes is mainly contributed by the tip of the
tandem. Rotating the tandem away from the midline where the nodes are located will move
the dose away. Figure 14d shows that as the system was shifted further away from its original
location, dose to the distal pelvic nodes decreased. This is reasonable since most shifts in
system between the first and second ICBT fractions were in the anterior and inferior
46

direction, as shown in Figure 11. Both shift directions will move the dose cloud away from
the distal pelvic nodes.
For the seven patients with positive distal pelvic nodes, tandem length differences
varied between -1 cm to 1 cm between ICBT1 and ICBT2. We originally hypothesized that
tandem length difference significantly correlates with distal pelvic nodes because increases in
tandem length would move the tandem tip closer to the nodal regions and the opposite effect
occurs when tandem length is shortened. However, correlation tests showed no significance
between the two factors. The reason for that is the location of the tandem tip relative to
patient anatomy is dependent on two factors, tandem length and system location in the SI
direction. For example, one of the patients with decreased distal pelvic nodal dose from the
second ICBT fraction also had a 1-cm longer tandem in ICBT2. However, its system location
shifted 1.8 cm in the inferior direction. The tip of the tandem is actually 0.8-cm lower in the
second ICBT fraction, thus causing lower distal pelvic nodal dose. Therefore, tandem length
alone is not a predictor of nodal dose differences.
2.5.3 Differences in Result between Mean Dose and D90
Because nodes are volumetric structures, it is not trivial to pick a point dose to
describe the dosimetric properties of the entire nodal volume. Traditionally, mean dose has
been used to describe nodal dose since nodes are typically small. However, when the dose
gradient within the nodal structure is high, which is normally the case for ICBT, prescribing
based on mean dose could lead to areas of underdose. Therefore, in addition to studying
differences in mean dose, we studied differences in D90. Prescribing nodal boost on the basis
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of D90 guarantees that underdosage may occur in at most 10% of the target. For proximal and
distal pelvic nodes, the mean±1SD differences between ICBT1 and ICBT2 were closer to
zero when D90 is used instead of mean dose: 5.2±69.8 cGy and 8.6±85.1 cGy for proximal,
respectively, and -21.9±38.4 cGy and -46.8±55.3 cGy for distal, respectively. There results
show that because of the dose gradient in the nodes, there are fewer differences in nodal dose
in the low dose region. Using mean dose to represent entire nodal dose when analyzing nodal
dose differences from independent ICBT fractions will result in an overestimation in the low
dose region, thus not cause underdosage in the nodes.
2.5.4 Limitations and Assumptions
In this work, we made several assumptions. First, we assumed that the film images
were orthogonal and were obtained exactly at 0° and 90°. However, although very close, this
may not be exact for every patient because the films were obtained in the operating room
with a portable computed radiography system. The film plate and x-ray unit may not be
exactly perpendicular since they are independent entities. However, during treatment
planning in Oncentra, common points on the orthogonal films were used by the treatment
planning system to create a three-dimensional space model as accurately as possible. This
ensures that the dose distribution is correct even when the films are not exactly orthogonal.
Also, since DRRs are generated at exactly 0° and 90°, aligning them to films that are not
exactly orthogonal might create misregistration. Second, we assumed that nodal regions are
not deformed by applicator insertions. Previous studies at our institution have shown that
applicator insertion has minimal effect on dose distribution of the nodes (90). Finally, the
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method used to normalize ICBT prescription—normalizing ICRU point A dose—is crude.
Although point A is one of the methods of evaluating dose prescription, it certainly does not
provide all the information about the dose distribution. However, normalizing point A dose
does improve consistency and is better than not normalizing at all.
2.6 CONCLUSION
We have demonstrated that the mean dose to the pelvic nodes can differ by up to 1.9
Gy between independent ICBT fractions. Tandem angle and total system shifts were found to
impact distal pelvic nodes while AP/PA and lateral shifts were found to impact proximal
pelvic nodal dose. Intracavitary brachytherapy can make a significant contribution to the total
dose delivered to pelvic lymph nodes. Although the dose delivered from a single system is
often a good predictor of the overall contribution from brachytherapy, in some cases the dose
delivered from separate treatments in the same patient can vary significantly. This should be
carefully considered in the overall planning of treatment for patients who have evidence of
lymph node metastasis.
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Chapter 3: Voxel-by-Voxel Bladder and Rectum Dose Accumulation
between External Beam Radiation Therapy and Intracavitary
Brachytherapy
3.1 SPECIFIC AIM 2
Develop and validate deformable image registration methods for the use of
volumetric summation of bladder and rectum dose from ICBT to an external beam planning
CT image set.
3.2 INTRODUCTION
3.2.1 Importance of Accurately Evaluating Total Bladder and Rectum Dose for the
Prescription of Nodal Boost
During the prescription of external beam nodal boost, dose to the bladder and rectum
is a major constraint on how much radiation can be delivered to the positive lymph nodes.
For radiation therapy of cervical cancer, dose tolerances for maximum bladder and rectum
point dose are 80 Gy and 75 Gy, respectively (91). As mentioned in Chapter 1, maximum
doses to the bladder and rectum can be estimated by summing the EBRT prescription dose
(this is done because a great portion of bladder and rectum are included in the primary EBRT
field) with ICRU bladder and rectum point from ICBT. However, when conformal methods
such as IMRT are used, this method becomes invalid because IMRT dose is heterogeneous
with unpredictable hot and cold spots. Unless the maximum dose points from both EBRT and
ICBT coincides at the same spot, simple dose summation can only represent the worst case
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scenario and total organ dose will be overestimated. In order to accurately determine
maximum organ dose, dose summation of bladder and rectum must be performed
volumetrically.
3.2.2 Image registration
Image registration is the process of transforming different sets of data into one
coordinate system. The process involves a ‘static’ and a ‘moving’ image, with the moving
image transformed into the coordinate system of the static image. There are two major types
of image registration, rigid and deformable. Rigid registration aligns two image sets by
rotation, translation, scaling, or shearing. Since each of these transformations provides 3degrees of freedom (ie. roll, pitch, and yaw for rotation and RL, AP, and SI shifts for
translation) there are a total of 12 possible degrees of freedoms for rigid registration. Because
rigid registration is a global process, its applications are limited and mostly used for cases
where the anatomy does not change between images. In radiation therapy, rigid registration is
mostly used in image guided radiation therapy (IGRT) where daily x-ray or CT images are
taken prior to treatment and compared to digital reconstructed radiographs (2D/2D matching)
or planning CT (3D/3D matching) respectively, for daily patient setup (92-94).
For organs that change shape non-rigidly, such as bladder and rectum, rigid
registration is inadequate and deformable image registration (DIR) must be used. DIR is a
voxel mapping process. Instead of registering the images globally, the algorithm looks to find
corresponding voxels on the static and moving images. Since each voxel is registered
independently, the number of degrees of freedom becomes infinite. There are two major
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categories of DIR algorithms, feature-based and intensity-based. Feature-based algorithms
are also often referred to as point-based or model-based methods. It extracts features, such as
points, curves, and surfaces on the static and moving images to finds its correspondence (9599). Feature-based methods are normally very fast but require robust feature extraction to
produce accurate results. On the other hand, intensity-based methods only require
information from the image intensity values (100-104). It finds correspondence by
maximizing an intensity similarity measure while also producing smooth transformations.
Image intensity algorithms involve excessive computational power and pre-registration of the
static and moving images must be performed to prevent the algorithm from being trapped by
local minima.
Although there are differences between feature and intensity-based methods, both
result in a vector field describing the transformation between the static and moving image.
The field contains vectors indicating the direction and magnitude of transformation needed
for each voxel on the moving image to match its corresponding voxel on the static image
(Figure 15). The deformation field by itself is not very useful in radiation therapy. However,
it can be used as a guide for contour and dose deformation, depending on the clinical needs.
The deformation field is applied to the contours or dose from the moving image so users can
view and evaluate them on the static image.
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Figure 15: Example of a static (inhale) and a moving (exhale) image taken from a 4dimensional CT image set. Deformation field resulted from DIR are shown on
the moving image. We can see that in order for the exhale phase to be deformed
to match the inhale phase, voxels (especially ones near the diaphragm) must be
transformed inferiorly resulting in expansion of the lungs.
3.2.3 In-house accelerated demons algorithm
The intensity-based DIR method used in this project was first proposed by Thirion
(103). It is referred to as the demons algorithm based on its analogy with Maxwell’s demons
(105). The demons algorithm uses the intensity of both static and moving images and the
gradient of the static image to find correspondence between the two. The equation for the
demons algorithm is:
𝑣⃗ =

�⃗𝑠
(𝑚−𝑠)∇
2

�⃗𝑠� +(𝑚−𝑠)2
�∇

(1)

with m and s indicating voxel values on the moving and static image, (m – s) indicating the
registration force between the images, and �∇⃗𝑠 representing the gradient of the static image.

Equation 1 is calculated iteratively for each voxel until the solution converges. In areas of

low gradient, the original demons algorithm becomes inefficient. To solve this problem and
53

increase speed, Wang et al. (104) added an active force to the original diffusion process. If
we make the assumption that diffusion of the images is bi-directional, the active force is the
force which allows the static image to diffuse into the moving image. This lowers the number
of iterations needed for the demons algorithm to converge and increases speed of registration.
The equation for “accelerated” demons algorithm is:
𝑣⃗ = (𝑚 − 𝑠) × �

2
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2
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The first term inside the second bracket is the passive force as shown in Equation 1 and the
second term is the active force. The α2 term was added to the denominator of the terms in the
brackets to limit the step size of each iteration to 1/(2α). Therefore, even with large
differences between (m – s), the algorithm cannot make large jumps during any iteration. A
Gaussian filter with a variance of σ2 is applied to the result after each iteration to smooth,
suppress noise, and preserve geometric continuity of the deformation field.
To further speed up the algorithm, prevents results from being trapped by local
minima, and limits the effect of large deformations Wang et al. also implemented a multiresolution approach (104). The algorithm is initially calculated at an image resolution that is
much coarse than the original. When the solution converges, the resolution is increased and
the displacement fields from the previous calculations are used as starting points for the next
round of iterations. This process is repeated multiple times until the original image
resolution is used.
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3.2.4 Using DIR for Dose Summation of Bladder and Rectum
With increasing number of commercially available image registration software, usage
of DIR for the purpose of dose summation has increased dramatically in recent years.
Currently, most dose summation using DIR are performed in regions where anatomical
deformations are reproducible and small, such as different phases of the breathing cycle in
the lungs (106). On the other hand, dose summation for bladder and rectum has remained a
challenging task. Problems caused by extremely homogeneous features and greatly varying
sizes make accurate voxel-by-voxel registration in the bladder very difficult. In the rectum,
the major problem with using DIR is the variable rectal filling and gas content. Gas content is
especially difficult to address because it may not have corresponding voxels on the aligned
images. Errors arise in our image intensity based DIR algorithm when corresponding voxels
simply does not exist.
Volumetrically summing bladder and rectum dose between EBRT and ICBT is an
even more difficult task. In addition to the problems just described, there are several
additional issues which need to be considered. First, the ICBT CT images contain the
brachytherapy applicator, Foley balloon and catheter, and vaginal packing; all are
nonexistent on the EBRT CT images. Second, the bladder is empty during ICBT which is not
the case in EBRT, thus causing large bladder deformations between EBRT and ICBT images.
Finally, the vaginal packing is intended to push the bladder and rectum away from the
applicator. This causes large and unnatural shifts in bladder and rectum location between
EBRT and ICBT. The purpose of this project is to develop and validate a voxel-by-voxel
dose summation method for the bladder and rectum between EBRT and ICBT CT image sets.
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With more accurate understanding of the total organ dose, radiation oncologists can consider
nodal boost prescription escalation without any concern about normal tissue complexities.
3.3 METHODS AND MATERIALS
3.3.1 Patient Cohort
Twenty patients were selected retrospectively for this study. All patients were initially
part of a prospective Internal Review Board approved protocol. The patients had clinical
stage IB to IVA cervical cancer and were treated between August 2008 and June 2011.
Patients were selected based on the criteria of having CT image sets for both external beam
radiation therapy and ICBT. Patients were treated using different types of brachytherapy
applicators: 14 patients were treated using a unique shielded but CT artifact-free FletcherSuit-Delclos tandem and ovoid applicator (107, 108), 2 received tandem and mini applicator,
2 received tandem and ring applicator, and 2 received tandem and cylinder applicator. All
applicators were manufactured by Nucletron (Nucletron, Netherlands), CT compatible, and
CT image artifact free. It is extremely important that the applicators used do not cause
artifacts on the CT images because it would compromise image registration results.
3.3.2 Contour Based Validation Metrics
One method of validating DIR algorithms is by evaluating deformed contour results.
Unlike deformed dose, the accuracy of deformed contours can be easily determined. Since
the human brain can process gray-scale images much more effectively than computers (109),
bladder and rectum contours delineated by radiation oncologists can be used as the ground
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truth for DIR validation. In this study, a single radiation oncologist delineated bladder and
rectum contours on both external beam planning CT images (EBRT-CT) and ICBT planning
CT images (ICBT-CT). Patient bladders were delineated to include the Foley balloon, and
patient rectums were delineated from the level of the distal end of the sigmoid colon to that
of the ischial tuberosities (110). An example of the contours and the DIR results are shown in
Figure 16. To validate the accelerated demons algorithm for bladder and rectum, we
deformed radiation oncologist delineated contours from EBRT-CT to ICBT-CT. The
deformed contours on ICBT-CT were then compared with delineated contours using volume
ratios, Dice’s coefficient (111, 112), and mean absolute distance. Volume ratio is calculated
by dividing the deformed region volume by the delineated region volume, Vdeformed/Vdelineated.
Dice’s coefficients are calculated using the equation:
𝑠=

2|𝑋∩𝑌|
|𝑋|+|𝑌|

(3)

where X and Y are the different contoured regions. Dice’s coefficient measures the similarity
between two contoured volumes. More specifically, the formula represents the size of the
union of the two sets divided by their average size. The result ranges between 0 and 1, with 0
being no overlap and 1 indicating perfect agreement. Finally, mean absolute distance is
calculated by taking the mean of the distances from deformed contours to the nearest point
on the delineated contour. The evaluation metrics were calculated independently for bladder
and rectum.
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Figure 16: Example showing the differences between EBRT-CT and ICBT-CT with the
bladder (yellow) and rectum (blue) delineated by a radiation oncologist. The
image on the right shows deformed contours (colorwash) mapped onto the
ICBT-CT image. One can see that neither bladder nor rectum agreed well with
radiation oncologist delineated contours.
3.3.3 Binary deformation
Evaluating the results using validation metrics presented in Section 3.3.2 have shown
that bladder and rectum deformation results between EBRT-CT and ICBT-CT were
extremely poor when image registration relied on image intensities alone (further details will
be provided in Section 3.4.1). In order to improve registration results, it was necessary to
provide extra information to the DIR algorithm in addition to the image intensities. Our
proposed method to improve DIR results was to force the organ boundaries to match. To do
so, we converted both CT images to binary images based on the delineated contours. All the
voxel CT numbers within the contours were changed to 1000 and everything outside was
changed to 0, as shown in Figure 17. Because the demons algorithm forces the moving image
to diffuse toward the gradient, a definitive binary boundary will force the boundaries to
match. Once all images were converted to binary and the binary EBRT-CTs were deformed
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to binary ICBT-CTs, deformation results were evaluated once again using volume ratio,
Dice’s coefficient, and mean absolute distance.

Figure 17: Example of binary EBRT-CT and binary ICBT-CT generated based on radiation
oncologist drawn contours. The image on the right shows binary deformed
contours (colorwash) mapped onto the ICBT-CT image. One can see that
compared to using image intensities alone (Figure 16), both deformed bladder
(yellow) and rectum (blue) contours agreed very well with their delineated
counterparts.
3.3.4 Voxel-by-voxel Validation Method
Validating DIR results using contours only provide partial information about the
overall accuracy of the registration method. Bad boundary agreement means the registration
results were poor. On the other hand, good boundary agreement means the results are better,
but is not enough to evaluate the accuracy of registrations for voxels within the contours. In
order to validate the accuracy of DIR algorithms for the use of dose accumulation, a voxelby-voxel method must be used. In this study, we proposed a novel method to generate a pair
of artificial CT images with known deformation between them so that we are able to test our
DIR algorithm by comparing the calculated deformation field with the known deformation
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field. A few criteria must be met for the results to be clinically relevant. First, the artificial
images must be created using population data in order to represent an entire population, not
just a single patient. Second, the images must simulate real clinical situations, in our case,
deformation in bladder and rectum between EBRT-CT and ICBT-CT images. Finally, we
must know the exact deformation field between the two images in order to use it as ground
truth.
The method we used to create population based artificial CT images is based on the
active shape model proposed by Cootes et al. (113). The active shape model captures the
most prominent variations of certain structure from a population of the structure shapes
through principal component analysis technique. In our method, variations between two
shapes are represented by a deformation field in a 3D space. The first step is to determine the
average variability of shapes within a population and calculate the mean deformation, 𝒅.

Second, the modes of variations, P, are calculated by applying principle component analysis
to the population of deformation fields. 𝑷 = (𝒑1 , 𝒑2 , … , 𝒑𝑡 ) is the matrix of the first 𝑡

eigenvectors in the principal component analysis, which represents the most prominent
variations (at least 90% of the total variations) deviating from the mean deformation. A new
deformation can then be generated from the population model using the equation:
𝑑 = 𝑑 + ∑𝑡𝑖=1 𝑏𝑖 𝑝𝑖

(4)

where bi is generated randomly and represents the deformation contributed by the ith mode of
variation. In order to ensure the deformation is reasonable, a maximum value, 𝐷max , is
enforced on the generation of random number bi according to equation 5:
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𝑏2

2
∑𝑡𝑘=1 � 𝑘2 � ≤ 𝐷max
𝜆
𝑘

(5)

Using this method, we can generate a new random deformation field, which can be applied to
a reference CT image set to generate artificial CT images resembling real human CT images.
We applied the aforementioned method to our patient population to obtain the interpatient and intra-patient variations to generate artificial CT images which represent an entire
population and have clinically relevant deformations between EBRT-CT and ICBT-CT.
Knowing the inter-patient variations allows the creation of population artificial CT images.
Intra-patient variations indicate the amount of deformation between EBRT-CT and ICBT-CT
for each patient.
To determine inter-patient variations, we first chose one of the 20 patients as the
reference patient. The reference patient was chosen to represent the approximate median of
the population. We also made sure the reference CT image sets, termed EBRT-CT Ref and
ICBT-CT Ref, had high contrast-to-noise ratio and were free of artifacts. To generate the
inter-patient deformation field for EBRT-CT, the CT image sets of the remaining patients
were aligned to the reference patient using our DIR algorithm, creating 19 deformation fields
(EBRTx - EBRT Ref), as shown in Figure 18. The fields were then used to generate the
population sampled deformation field (Inter-Patient Deformation Field), shown in Figure 19.
When the Inter-Patient Deformation Field is applied to the EBRT-CT Ref image, it creates an
artificial CT image (EBRT Artificial CT) which represents the population in the study
(Figure 20).
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Figure 18: Using a reference patient to create a group of deformation fields.
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Figure 19: The group of deformation field is then used to create a inter-patient deformation
field.

Figure 20: Using the Inter-Patient Deformation Field, we generated an artificial population
CT image.
To create the population set which represents variability between EBRT-CT and
ICBT-CT, we first deformed the EBRT-CT to its corresponding ICBT-CT for all patients
(Figure 21). Once we have the deformation fields for all patients, we generated a intra-patient
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deformation field using the same method as before (Figure 22). The resulting deformation
field (Intra-Patient Deformation Field) represents the principle anatomical variations between
external beam CT images and brachytherapy images. Also, to create the ICBT Artificial CT
image, we needed to know the deformation field between the two reference images (Ref Def
Field), as shown in Figure 23. Generating the ICBT Artificial CT image is not as straight
forward as generating the EBRT Artificial CT image. The detailed process is shown in
Figure 24. The concept is to first spatially transform the ICBT-CT Ref image to the EB-CT
Ref image, while retaining ICBT characteristics (contains applicator, Foley balloon, etc.).
This image with the ICBT characteristics was then spatially transformed into the space of
EBRT Artificial CT image using Inter-Patient Deformation Field. Finally, we created the
ICBT Artificial CT image by further applying the Intra-Patient Deformation Field. An
example of EBRT Artificial CT and ICBT Artificial CT generated using Dmax = 2 is shown in
Figure 25. The variability between EBRT Artificial CT and ICBT Artificial CT is the IntraPatient Deformation Field and that is our known field.
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Figure 21: Creating a group of deformation fields between external beam CT images and
brachytherapy images.
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Figure 22: Using the group of intra-patient deformation fields to create a population
deformation field between external beam radiation therapy and brachytherapy
CT images (Intra-Patient Deformation Field).

Figure 23: The deformation field between the Reference images (Ref Def Field) is needed for
creating the simulation ICBT image.
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Figure 24: In order to create the ICBT Artificial CT, the original ICBT-CT Ref must go
through a few transformations into different CT image space.

Figure 25: Example of EBRT Artificial CT and ICBT Artificial CT generated using Dmax = 2.
Since our choice for Dmax is not large, the deformation between the two images
is not as severe.
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3.3.5 Validation of Deformation Results
Using the artificial CT image pairs generated by the method described in Section
3.3.4, we could validate the deformation results for the bladder and rectum. By subtracting
the deformed field from the known field, we can quantify differences in the RL, AP, SI
directions and total magnitude for each voxel. The total magnitude was calculated by taking
the root of the sum of squares in the three directions. The mean difference of all voxels was
reported as the error in registration. We then converted the simulated CT images into binary
images as described in Section 3.3.3 and repeated voxel-by-voxel validation for the bladder
and rectum. To test DIR accuracy with varying amounts of deformation, we validated the
normal and binary deformation results with Dmax set at 2, 3.5, and 4.5.
3.4 RESULTS
3.4.1 Contour Based Validation
Results from contour based validations are shown in Table 2 and 3. By using a binary
method instead of image intensities alone, the deformed contours have shown much better
agreement with delineated contours. On average, the Dice’s coefficient increased by 0.39 and
0.41 for the bladder and rectum, respectively. The mean absolute distance decreased by 5.6
mm for both organs. Typically, when judging similarity of two regions based on Dice’s
coefficient, which ranges from 0 to 1, a value of 0.7 is considered acceptable and 0.8 is
considered good. When deforming using normal methods, Dice’s coefficient for the bladder
and rectum exceeded 0.7 in 8 of 20 (40%) and 0 of 20 (0%) patients, respectively. When the
criteria is raised to 0.8, only 3 of 20 (15%) bladders and 0 of 20 (0%) rectums exceeded it.
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On the other hand, when binary methods are used, all 20 bladder and 19 of 20 (95%) rectum
deformations exceeded a Dice’s coefficient of 0.8.
Table 2: Evaluation of contour agreement between deformed and delineated for bladder using
image intensity alone (Normal) and Binary methods.
Bladder
Normal
Mean+1SD Range
Volume Ratio
1.04+0.45 0.36-1.86
Dice
0.57+0.2
0.2-0.88
Mean Absolute Distance (cm) 0.65+0.29 0.23-1.06

Binary
Mean+1SD Range
0.98+0.02 0.93-1.01
0.96+0.02 0.92-0.98
0.09+0.02 0.05-0.13

Table 3: Evaluation of contour agreement between deformed and delineated for rectum using
image intensity alone (Normal) and Binary methods.

Volume Ratio
Dice
Mean Absolute Distance (cm)

Rectum
Normal
Mean+1SD
Range
0.91+0.44 0.25-1.88
0.5+0.1
0.3-0.66
0.69+0.23 0.39-1.31

Binary
Mean+1SD
Range
0.95+0.06
0.75-1.05
0.91+0.04
0.79-0.95
0.13+0.07
0.07-0.35

3.4.2 Mean Error from Voxel-by-Voxel Validation
Mean differences of all voxels between deformed and known deformation fields in
the RL, AP, SI, and total magnitude are shown in Table 4. The mean error in registration for
the bladder using image intensity alone (Normal) DIR methods were 0.98 mm, 1.09 mm, 0.17 mm, and 3.47 mm in the RL, AP, SI, and total magnitude, respectively. Using the binary
DIR method, the mean errors in registration for the bladder were 0.24 mm, -2.76 mm, -1.33
mm, and 4.61 mm in the RL, AP, SI, and total magnitude, respectively. For the rectum, the
mean errors in registration using Normal DIR methods were 0.02 mm, -0.86 mm, -0.37 mm,
69

and 2.74 mm in the RL, AP, SI, and total magnitude, respectively, while the mean errors in
registration using binary DIR methods were 1.39 mm, 1.54 mm, 3.19 mm, and 5.6 mm in the
RL, AP, SI, and total magnitude, respectively. Figure 26 shows an example of the histograms
for bladder and rectum voxel misregistration using normal and binary methods when Dmax is
set to 2.
Table 4: Mean errors in registration (mm) for all voxels in the bladder and rectum.

RL
AP
SI
Mag

Dmax
Normal
Binary
Normal
Binary
Normal
Binary
Normal
Binary

2
1.38
0.84
1.12
-2.73
0.64
-1.38
3.32
4.11

Bladder
3.5
1.44
-0.30
0.86
-3.25
-0.70
-1.26
3.69
5.09

4.5
0.12
0.19
1.30
-2.30
-0.44
-1.35
3.41
4.64
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2
0.09
1.76
-0.51
1.95
-0.22
2.81
2.51
5.28

Rectum
3.5
-0.14
1.34
-1.06
1.23
-0.12
3.48
2.73
6.08

4.5
0.11
1.09
-1.00
1.46
-0.76
3.28
2.98
5.43

Figure 26: Histogram of errors in registration between deformed and known deformation
fields. Both bladder and rectum were analyzed using normal and binary
deformation methods. Dmax in this example was 2.
3.5 DISCUSSION
3.5.1 The importance of voxel-by-voxel validation
With the increasing availability of commercial software which offers FDA approved
DIR tools for volumetric dose summation, it is even more crucial to develop voxel-by-voxel
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validation tools to understand the magnitude of uncertainties associated with DIR algorithms.
In a recent point/counterpoint published in Medical Physics, the appropriateness of adaptive
radiation therapy using dose deformation was hotly debated (114). Although both sides were
debated, the consensus was that accurate DIR is a difficult clinical problem which requires
full understanding of the limitations from both physicists and radiation oncologists in order
to be safely used in the clinic. Quantifying registration errors is the first step toward
understanding limitations and determining appropriate uses of DIR.
Currently, the three most commonly used methods of voxel-by-voxel DIR validation
use anatomical landmarks, anthropomorphic phantoms, and mathematical phantoms. In
regions where anatomical landmarks are easily seen and can be reproduced accurately,
landmarks are identified on both static and moving images. After DIR between the two
images, landmarks on the deformed moving image is compared to landmarks on the static
image. Differences in landmark locations between the two are the errors in registration. Most
common uses of landmarks for DIR validation are in the thoracic or liver regions where
bronchial or vessel bifurcations can be accurately identified (96, 115). Another method for
DIR validation is by using anthropomorphic phantoms which can be physically deformed to
a known amount. For example, Kirby et al. (116, 117) built a head & neck and a pelvic
phantom which contains glow in the dark optic markers that are CT transparent. This is
useful because the optical markers do not influence DIR results. When the phantoms are
deformed, the deformation fields can be measured optically and compared with DIR
calculated deformation fields based on the pre and post deformed CT images. Finally, one
can take a CT image and artificially create simple deformations using software to generate a
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new CT image. DIR algorithms are tested by deforming the new CT image with the original
CT image and compared with the applied deformation (104, 118).
Established methods such as landmarks or phantoms are not ideal for this study.
Unlike thoracic or liver regions where bronchial or vessel bifurcations can be accurately
identified, bladder and rectum lack landmark points which may be used for validation. Also,
building an accurate anthropomorphic volumetric phantom of the female pelvis with the
ability to mimic bladder and rectum changes after an ICBT applicator insertion is not trivial.
There are a few reasons why our validation method is novel and advantageous compared to
other available methods. First, our method utilizes and creates realistic patient CT images
without having to physically build a phantom. This makes the process extremely simple and
can be used widely by many clinics with their own patient database. Second, the known
deformation field is generated using population data. Therefore, the artificial deformations
are clinically relevant and represent real patient anatomical variations. Third, we have
provided a method to generate artificial ICBT images while still maintaining the known
deformation field between it and the artificial EBRT-CT image. Finally, although we only
validated our method for the bladder and rectum between the EBRT-CT and ICBT-CT
images, our proposed method can be used for any site and any DIR algorithm. Institutions
wishing to validate their in-house or commercial DIR programs can easily do so by
generating artificial images with known deformation fields for their organs of interest and
patient population using the guidelines provided in this study.

73

3.5.2 Comparing Binary and Normal Methods Using DIR Evaluation Metrics
As Table 2 and 3 have shown, using image intensity alone for DIR of EBRT-CT to
ICBT-CT resulted in very poor agreement at the boundaries. This is not a surprise since we
already anticipate deformations in the bladder and rectum region is large. Also, constraints
are placed in the DIR algorithm to prevent large “unrealistic” deformations. When
deformations are actually large, the maximum deformation vector magnitude allowed is the
calculation result instead of the true deformation. Using image intensities alone, the mean
Dice’s coefficient for both bladder and rectum is only around 0.5 or 50% similarity between
deformed and delineated contours. Even without voxel-by-voxel validation, we can make the
conclusion that image intensity alone will not be appropriate for dose summation between
EBRT-CT and ICBT-CT. If the boundaries are incorrectly deformed, voxel registrations
within the boundaries are going to be incorrect as well. By converting the images to binary
images, we forced the boundaries to match, which in theory should improve registration
results. Our results have shown that by using the binary method, the boundaries matched
extremely well even with large deformations.
Before discussing the results from our voxel based validation method, the limitations
and drawbacks of the binary method need to be listed. First, human interaction is required for
the binary process. The organs of interest must be manually delineated on both static and
moving images. This is not required if using image intensity alone. The accuracy of the
deformation results also becomes highly dependent on the accuracy and consistency of the
delineated contours. Second, by converting images to binary, we lose the image information
within the contours. Since all voxels within the volume are have CT number of 1000, the
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deformations of the inner voxels are essentially interpolated based on where they are located
and the amount of deformation at the boundary.
Comparing registration results for the bladder and rectum on our artificial images. We
observed that overall errors in registration are less for the normal image intensity
registrations. This is unexpected since the boundary validations have shown better results
using the binary method. Upon reviewing the artificial images, we concluded that one of the
main reasons image registration results were good for our artificial images was because the
chosen Dmax were small. Since Dmax determines the maximum amount of deformation that
could be created, we did not generate the extreme organ deformations which were observed
between EBRT-CT and ICBT-CT. To test this theory, we increased the Dmax value from 2 to
3.5 and 4.5. When we increased Dmax, DIR becomes less accurate for both image intensity
and binary registration methods, as shown in Table 4. We also observed that increasing Dmax
affected image intensity registrations more than binary registration. This is because binary
registrations are much better at handling large deformations than image intensity based
registrations. Figure 27 shows a sagittal view of the bladder and rectum with the total
magnitude of error for each voxel. For image intensity based registration (Normal), the
regions with accurate and inaccurate registrations were scattered throughout the region. For
binary registration, the more accurate regions were in areas where deformations were small.
On the contrary, less accurate regions were located in areas with large deformations.
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Figure 27: Sagittal view of total magnitude registration errors for normal and binary methods
for each voxel. One can see that errors in registration on the normal method
occurred at places where voxels lacked correspondence between the EBRT-CT
and ICBT-CT images. For the binary method, registration errors were greatest
in regions where deformation was large.
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Comparing our registration results to results found by other research groups, we
found that our results were very much in line with published data, which varied between 2 to
7 mm (96, 104, 115-118). We found that mean errors in bladder and rectum registrations are
3.5 mm and 2.7 mm for image intensity registrations, respectively, and 4.6 mm and 5.6 mm
for binary registrations, respectively. The advantage of our voxel validation method is that
our results are patient population, organ, and DIR algorithm dependent. The results of this
work are specific to our demons algorithm and for bladder and rectum deformations between
EBRT-CT and ICBT-CT.
3.6 CONCLUSION
We have created a method to improve DIR of the bladder and rectum between an
external beam CT image and an ICBT CT image. We also developed a voxel-by-voxel
validation method to quantify the errors in registration. By doing so, we have explored the
limitations in such DIR process so that physicist and radiation oncologists can have better
understanding of what the deformation results mean and how it can be used clinically.
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Chapter 4: Beam Angle Specific Margins to Account for Anatomical
Uncertainties during Proton Therapy in Nodal Boost Planning for Cervical
Cancer
4.1 SPECIFIC AIM 3
Calculate nodal boost planning margins needed for proton therapy to account for
interfractional anatomical variations.
4.2 INTRODUCTION
In recent years, proton therapy has become more mainstream and accessible to
patients needing radiation therapy. According to the Particle Therapy Co-Operative Group,
as of February 2013, there are 11 centers in operation and 8 under construction in the United
States alone (119). The main attraction of protons therapy is that the beam has finite range
and delivers almost all of its energy at the end of its range (termed the Bragg peak); almost
no energy is deposited beyond the Bragg peak. Clinically, this feature of protons is extremely
advantageous because all organs beyond the distal edge of the beam can be spared from
radiation. Unfortunately, CT number, beam energy, setup, and patient motion uncertainties
can all affect the proton range (120, 121). Currently, a simple method is used to account for
such uncertainties: 3.5% of the spread-out Bragg peak is applied as distal and proximal
margins, as proposed by Moyers et al. (122). However, current methods rarely explicitly
account for patient’s interfractional anatomy changes, which could have a big effect on target
coverage.
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In patients with involved pelvic lymph nodes, nodal boost with radiation (“boost”) is
given to increase the total dose to the involved nodes to 60 to 66-Gy (79). Although nodal
involvement from cervical cancer may occur anywhere along the lymphatic drainage
pathway, cervical cancer most commonly spreads to the external iliac nodes and common
iliac nodes (77, 78). Currently, though nodal boost doses are typically delivered using
external beam photon therapy, proton therapy can generate theoretical dose distributions
unmatched by photons for nodal boosts. For example, a single PA proton beam can be used
to deliver conformal dose to external iliac nodes. Small bowel will be spared because it lies
beyond the distal margin. However, uncertainty related to interfractional anatomical changes
need to be considered thoroughly in order to use proton therapy to target the nodal boost
volume.
Dosimetric differences caused by interfractional anatomical variations are magnified
in nodal boosts because a very small target is irradiated over a small number of fractions.
Any variation in anatomy in the beam path can cause the proton beam edge to shift off the
target, resulting in undercoverage in either the distal or proximal end of the target. Shifts in
distal and proximal edges of the beam may also potentially move the high dose region into
adjacent normal tissues, causing complexities. Thus, adequate distal and proximal margins
must be used during proton nodal boost planning to account for anatomical uncertainties, in
addition to the uncertainty of CT numbers (122). Modeling and predicting interfractional
anatomical changes is not trivial. Anatomical variations are dependent on target location,
target size, and beam angle.
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The purpose of this aim was to develop a general approach to determining the
margins needed to account for interfractional anatomical variations during proton therapy.
We applied this approach to determine the optimal beam orientation and required margins for
delivery of radiation boost to external iliac and common iliac nodes using proton beams.
4.3 METHODS AND MATERIALS
4.3.1 Patient Cohort
Patients in this study were originally part of an Institutional Review Board approved
prospective study of internal organ motion in cervical cancer patients (22). Images obtained
from the previous study were retrospectively evaluated in this study. CT images from 16
patients with Stage IB2 through IIIA cervical cancer who had been treated with concurrent
chemoradiation without hysterectomy were used for this study. Eight patients had Stage IB2
disease, 1 had Stage IIA disease, 6 had Stage IIB disease, and 1 had Stage IIIA disease. Each
patient underwent a simulation CT scan prior to treatment planning, first with the bladder full
and then with the bladder empty, performed with a Philips AcQSim3 CT scanner (Philips
Medical Systems, Andover, MA) using our standard pelvic CT imaging protocol. All patients
received primary EBRT followed by 2 fractions of PDR ICBT. The EBRT fractionation
schemes used were 43.2 Gy in 24 fractions (6 patients) and 45 Gy in 25 fractions (10
patients). Patients also underwent a CT scan weekly prior to treatment, performed with an inroom CT-on-Rails system (GE Healthcare, Milwaukee, WI). Patients were weighed prior to
chemotherapy and at weekly check-ups to ensure no sudden weight loss or gain.
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4.3.2 Automatic Contour Delineation
In each patient, the goal was to design the radiation fields to cover the most
frequently involved external iliac and common iliac lymph nodes as identified in a study
recently published by Fontanilla et al. (77). To avoid interobserver and contour delineation
uncertainties, DIR using an in-house developed software (104) was used. The study by
Fontanilla et al. included an atlas in which PET-positive nodal locations from 45 patients
were summarized on a single reference CT scan. We designed the clinical target volume
(CTV) used in this study to cover external iliac nodal regions that were positive in at least
14% of patients in the Fontanilla et al. study and common iliac nodal regions that were
positive in at least 12% of the patients in that study. Since positive nodes may occur
anywhere along the lymphatic drainage, nodal regions positive in 12% of the patients is
considered high occurrence. Nodal contours from the atlas were deformed to each planning
CT. All deformed contours were expanded and smoothed using contouring tools in the
Pinnacle TPS version 9.0 (Philips Medical Systems, Andover, MA). Then, all contours were
verified and approved by a radiation oncologist.
4.3.3 Patient Setup
Currently, for proton therapy delivered at our institution, in-room kilovoltage x-ray
images are used for daily treatment setup alignment. The limitation of such a technique is
that only bony anatomy is visible in the image. In the case of nodal boost treatments, bonebased alignment method is sufficient since lymph nodes are typically fixed with respect to
bony anatomy. To simulate treatment scenarios for the current study, we delineated a pelvic
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bony region of approximately 2-cm in cranial-caudal dimension near the external iliac nodes
and a second region at the superior portion of the sacrum. Those regions were used as
alignment surrogates for the external iliac and common iliac nodes, respectively. Nodal
contours from planning CT were transferred to weekly CT images using rigid image
alignment of the delineated bony structures (92, 123). The rigidly aligned nodal contours on
the weekly images represented the actual dose delivery region without daily patient setup
uncertainties. Illustration of the process can be seen in Figure 28.

Figure 28: Simulation of daily treatment setup by transferring target contours (yellow) from
Reference to Daily CT image sets using bony structures (red).
4.3.4 Calculation of anatomical changes
In this project, we used the ray-tracing method to determine anatomical changes. The
method calculates the water-equivalent path-length of parallel rays in the direction of defined
beams from the patient surface to the distal and proximal surfaces of the target. The
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dimension of each ray size is equivalent to the voxel dimensions of the CT images.
Measuring differences in water-equivalent path-length between planning and weekly CT
images indicates the magnitude of change in the proton beam range. To evaluate the impact
of beam angle on the magnitude of range change due to anatomical variation, we evaluated 8
gantry angles for the treatment of common iliac nodes (from 0° to 315°, at 45° intervals) and
3 gantry angles (90°, 180°, and 270°) for the treatment of external iliac nodes. Using the raytracing algorithm, the distal and proximal edges of the nodal contours at each angle for every
CT image set were calculated. As shown in Figure 29, each ray-trace results in a 2dimensional matrix showing the water-equivalent path-length from the beams-eye-view.

Figure 29: A ray-tracing method was used to determine the water-equivalent path-length
(WEPL) from the patient surface to the distal and proximal edges of all targets.
Ray tracing is parallel to the treatment beam direction. This method results in
two 2-dimensional matrices that represent the distal and proximal WEPL map
for each target on any particular computed tomography scan.
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4.3.5 Margin calculation
To determine the margin required to ensure coverage of the target in each weekly CT
image, the reference water-equivalent path-length matrix (obtained on the planning CT) was
subtracted from each weekly matrix, pixel by pixel, for both distal and proximal edges
(Figure 30). The margin required to account for anatomical variations in the beam path on
any given weekly fraction was defined as the difference corresponding to the 95th percentile
of the differences of all the pixels. To determine the margin needed to cover the entire
population, all weekly margins were combined, and the mean plus 2 standard deviation was
used as the population margin.

Figure 30: After the water-equivalent path-length (WEPL) maps for both distal and proximal
surfaces were obtained on all planning and weekly computed tomography (CT)
images, the reference planning maps were subtracted from each daily map to
obtain the variation maps. The WEPL difference value to cover 95th percentile
of the pixels was used as the margin needed to account for anatomical variations
on that particular fraction. Multiple measurements were obtained for each repeat
CT image and a group of patients.
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4.3.6 Proton Therapy Planning Test Case
To determine the advantages and feasibility of using protons for nodal boosts for
cervical cancer, data from a typical cervical cancer patient who had been treated with photon
nodal boosts were used. The original clinical prescription for nodal boosts was 10 Gy in 5
fractions to the external iliac nodes and 6 Gy in 3 fractions to the common iliac nodes. Threefield IMRT plans were used for each node. The CT images and all contour delineations were
transferred from the original photon therapy plan to the proton therapy plan. Bowel was
delineated as the entire peritoneal potential space of bowel. A simulated proton therapy plan
was performed in the Eclipse Proton TPS (Varian Medical System, Palo Alto, CA). Two
single-field, uniform-dose scanning proton beams, 90° (right lateral) and 180° (PA), were
chosen to treat the common iliac region, and a single, 180° (PA) beam was used to treat the
external iliac nodes. These angles were chosen because they are associated with the least
interfractional anatomical variation (more details shown in Section 4.3.2). Current clinical
planning margins, which are 3.5% of the SOBP plus 3 mm, were applied to both distal and
proximal edges to account for stopping-power-ratio and dose calculation uncertainties,
respectively. The anatomical variation margins derived from this work were also included in
addition to current clinical margins. The target dose was normalized to provide coverage
similar to that with the original photon therapy plan. Differences in normal tissue dose were
analyzed.
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4.4 RESULTS
4.4.1 Patient Weight Changes
Out of the 16 patients, 6 patients had 4 weekly CT scans, 9 patients had 5 weekly CT
scans, and 1 patient had 6 weekly CT scans. The mean relative weight change between
weekly and planning CT scans in this cohort of patients was -2.3±2.7%, and the maximum
relative change was -8.6% (the negative sign represents a weight loss). Seven of the 16
patients had maximum weight loss of greater than 5%.
4.4.2 Distal and Proximal Margin Requirements for Common and External Iliac Nodes
Results for both common iliac and external iliac nodes are shown in Figure 31. For
the common iliac nodes, the angles with the greatest anatomical variations were 0° (AP), 45°
(left anterior oblique [LAO]), and 315° (right anterior oblique [RAO]). The population
proton margin requirements to account for interfractional variations for 0°, 45°, and 315°
were 1.9 cm, 1.7 cm, and 2.4 cm, respectively, for the distal edge and 3.0 cm, 2.6 cm, and 3.5
cm, respectively, for the proximal edge. The angles with the least anatomical variations were
90° (left lateral) and 180° (PA). The population planning margin requirements for 90° and
180° were 0.8 cm and 0.9 cm, respectively, for the distal edge and 1.7 cm and 1.4 cm,
respectively, for the proximal edge. The remaining angles, 135° (left posterior oblique), 225°
(right posterior oblique), and 270° (right lateral), fell somewhere between the 2 extremes,
with population margin requirements of 1.2 cm, 1.3 cm, and 1.3 cm, respectively, for the
distal edge and 2.1 cm, 2.1 cm, and 1.8 cm, respectively, for the proximal edge.
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For the external iliac nodes only interfractional anatomical uncertainties in PA and
lateral angles were analyzed because of the strong preference to avoid the central pelvis. For
left and right external iliac nodes, the PA margin requirements were 0.8 cm and 0.7 cm,
respectively, for the distal edge and 1.0 cm and 1.3 cm, respectively, for the proximal edge.
Lateral margin requirements for the left and right external iliac nodes were the same (0.3
cm), for the distal edge and 1.2 cm and 1.3 cm, respectively, for the proximal edge.
Combining the left and right nodes and choosing the worst case between the two in each
fraction revealed that the population margin requirements for the PA beams were 0.9 cm and
1.3 cm for the distal and proximal edges, respectively. For lateral beams, the population
margin requirements were 0.4 cm and 1.4 cm for the distal and proximal edges, respectively.
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Figure 31: Range margins for common (a) and external iliac (b) nodes were analyzed.
Several angles were selected to test the impact of beam angle on the magnitude
of change in the proton beam range due to anatomical variation. Box graphs
showing median, 75th percentile, 90th percentile, and outliers for both distal
and proximal variations are shown.
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4.4.3 Comparison of Photon and Proton Dose Distribution in Test Case
We found that the major difference between photon and proton nodal boosts was
bowel sparing. Figure 32 shows the dose distribution and dose-volume histogram differences
between IMRT and the single-field, uniform-dose proton plan for the sample patient. The
difference in target coverage between the 2 modalities was essentially zero, by design.
However, the proton dose to the bowel was approximately half the photon dose to the bowel
at all dose levels. Using metric guidelines from the Quantitative Analysis of Normal Tissue
Effects in the Clinic (QUANTEC) effort (23) indicated that the dose to the 195 cc of the
bowel region increased from 2.8 Gy with protons to 5.7 Gy with photons.
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Figure 32: Differences between the dose-volume histograms for intensity-modulated
radiation therapy (IMRT) and proton therapy for both common iliac and
external iliac nodes. Three-field IMRT plans were used for each node. A 2-field
proton plan was used for the common iliac nodes, and a single proton posterioranterior field was used for the external iliac nodes. The small bowel dose was
reduced by half with proton therapy.
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4.5 DISCUSSION
Accurate targeting in proton therapy requires the knowledge of range uncertainties
during treatment delivery. Interfractional variation of anatomy outside the treatment target
could introduce range uncertainties to cause proton beams to shift distally or proximally.
Adequate margins are necessary to ensure accurate proton beam delivery especially for
treating small targets. Large anatomical variations could potentially shift the distal or
proximal edge of the proton beam completely out of the target. It is also important to
evaluate range uncertainties as a function of proton beam angles. In this study, we proposed a
general approach to construct margins to account for interfractional anatomy variations. We
used a ray-tracing method and repeat in-room CT images to quantify beam-specific margin
requirement for a group of cervical cancer patients.
Previous studies by Hui et al. and Wang et al. looked at the effects of interfractional
anatomical variation during proton therapy (124, 125). However, in those studies, the
anatomical sites examined were lung and prostate, and the focus was on evaluating the
adequacy of established clinical treatment margins. This work went a step further by
calculating the actual required margins. Using protons to boost the dose to the nodes for
cervical cancer is a new idea, and the results from this work provide radiation oncologists
with adequate information to delivery such therapy with confidence.
4.5.1 Beam Angle Dependence of Interfractional Anatomical Variations
Our results indicate that proton beam uncertainties are very dependent on beam angle
selection. Beams passing through the bowel region required margins 2 to 3 times as large as
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beams passing at other angles. This is not surprising since bowel contents can vary greatly
from day to day, as illustrated in Figure 33a and b. In addition, beams passing through the
bowel are not favorable since bowel doses after primary EBRT and brachytherapy may
already be close to the maximum tolerated dose. Proton beams at 135° (left posterior oblique)
and 225° (right posterior oblique) required less margin than beams passing through the
bowel. However, the margin required to account for uncertainties at those angles was still not
small. As seen in Figure 33c and d, daily patient setup can greatly affect how much
subcutaneous adipose tissue lies between the patient’s skin surface and the target. This is the
main cause of interfractional variations at those angles. The angles with the lowest
uncertainties were the PA and lateral angles. These angles were less affected by bowel
content and setup uncertainties.
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Figure 33: Examples of anatomical variations at different beam angles. Bowel path
differences can be seen clearly in (a) and (b) for the 315° (right anterior oblique)
angle. Differences in subcutaneous adipose tissue can be seen in (c) and (d). In
both cases, differences in range are greater than the spread-out Bragg peak of
the beam.
4.5.2 Differences in Distal and Proximal Margin Requirements
Interestingly, our results showed a difference in the magnitude of the required distal
and proximal margins. In theory, variations in the beam path should be random. Distal and
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proximal required margins should be comparable. However, on average, the required distal
margin was 0.8 cm (range, 0.2 to 1.1 cm) smaller than the required proximal margin. We
hypothesized that weight loss was a major contributor to the asymmetric margin
requirements. Two-tailed Spearman’s rho correlations were used to test the statistical
significance of the correlation between patient weight change and margin requirements. For
common iliac nodes, margin requirements were significantly correlated (p<0.01) with weight
change for all angles for both distal and proximal margins except for distal margin
requirements at 270° (right lateral). For external iliac nodes, margin requirements were
significantly correlated with weight change for all proton beam angles. Correlation
coefficients also showed that the magnitude of the proximal margin was directly proportional
to the magnitude of weight loss and the magnitude of the distal margin was inversely
proportional to the magnitude of weight loss. This is reasonable since proximal margins are
required when patients lose weight because the beams will pass through less tissue, thus
overshooting the target. Overshooting the target will result in inadequate coverage at the
proximal edge. However, from a dosimetric point of view, the proximal fall-off of a proton
beam is gradual. The dosimetric impact may not be as significant as in the distal end.
4.5.3 Differences between Common and External Iliac Nodal Margin Requirements
Differences between margin requirements for common and external iliac nodes were
analyzed. For PA beams, margin differences between the 2 nodal regions were less than half
a millimeter. In the lateral directions, common iliac nodes required an average increase of 0.5
cm and 0.7 cm in the left and right sides, respectively. Once again, weight loss may be a
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major contributor to the difference in the lateral beams. Because patient weight loss usually
has the largest effect in the abdominal region, common iliac nodes are affected more.
4.5.4 Potential Small Bowel Sparing using Protons for Nodal Boost
Comparison of the IMRT plan with the single-field, uniformly optimized dose proton
plan revealed that the sparing in bowel dose was large. The QUANTEC guidelines
recommended that the volume of bowel treated to 45 Gy be less than 195 cc (23). However,
that dose limit could possibly already have been reached during primary EBRT. Therefore, it
is crucial that the small bowel receive minimal additional dose from the boost. With the extra
anatomical margins added into our proton therapy plan, it was impossible to totally avoid the
bowel region. Nevertheless, the dose to the bowel was reduced by half if protons were used.
With that stated, the main focus of this project was angle and margin determination. A
dosimetric comparison between proton and photons is beyond the scope of this study.
4.5.5 Assumptions and Limitations
One limitation of this study is the use of a simple ray-trace method. Although this
method is fast, it does not account for scatter within the medium. However, the ray-tracing
method as a fast dose approximation has been validated by Park et al. (126). In their work,
gamma analysis under 3% dose and 3-mm distance-to-agreement criteria was greater than
90%. Another limitation of our study is that CT images were obtained weekly instead of
daily. In our clinic, nodal boosts are given in a single week in 5 fractions. Patient may not
lose much weight during one week. In this study, we used weekly CT images (because of
their availability) and the interfractional anatomical variations are likely to be larger than the
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actual interfractional variations in one week. Therefore, the results from this work might
have overestimated the margin requirements, especially for patients who lose significant
weight.
4.6 CONCLUSION
We have demonstrated a systematic approach to determine population-based
anatomical margin requirements for proton therapy. Our ray-tracing approach is not limited
to the pelvis and nodal structures; it is universal and can be applied to any disease site. The
results of our study indicate that in cervical cancer patients requiring nodal boosts, the
optimal treatment angles for common iliac nodes are 90° (left lateral) and 180° (PA) with
additional 0.8-cm and 0.9-cm margins, respectively. For external iliac nodes, lateral and PA
beams required additional 0.4-cm and 0.9-cm margins, respectively. These results will allow
for safe delivery of proton therapy when delivering nodal boosts to patients with cervical
cancer.
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Chapter 5: Conclusion
5.1 SUMMARY OF THE PROBLEMS, PURPOSE, AND HYPOTHESIS
During a multi-course, multi-modality treatment of cervical cancer, the primary
EBRT, ICBT, and external beam nodal boost all contribute substantial dose to the lymph
nodes. In many cases, primary EBRT delivers sufficient dose to the nodes to treat
microscopic diseases. Radiation boost is only given to patients with positive lymph nodes
requiring dose escalation. Prescription of radiation for nodal boost is not straightforward.
Many considerations must be taken into account to prevent underdosing the nodal target,
which may lead to recurrence or metastasis of disease, while also not overdosing, which
could cause normal tissue complexities. Accurate radiation prescription for nodal boost
require exact knowledge of previously delivered dose from primary EBRT and ICBT to both
the targeted nodes and normal tissues. At MD Anderson, because the second PDR ICBT
fraction is delivered post nodal boost, some assumptions about the 2nd ICBT fraction must
be made during prescription of nodal boost, which require prior knowledge of potential
differences between the two ICBT fractions. Also, current methods of summing bladder and
rectum dose using maximum dose points could overestimate when conformal methods such
as IMRT are used. Volumetric dose summation needs to be used for more accurate
understanding of dose distributions in the normal organs. Prescription of nodal dose is only
half of the difficulty; the other half is dose delivery. When photons are used, setups of beam
angles always involve tradeoffs and compromises to avoid normal tissues.
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The purpose of this project is to improve external beam radiation therapy of
lymphatic nodal boost during a course of cervical cancer treatment by: 1) Quantifying
interfractional uncertainties. 2) Developing and validating dose accumulation tools between
external beam radiation therapy and brachytherapy. 3) Exploring alternative treatment
modalities.
The hypothesis of this project is separated into three parts. First, rigid 2D-3D image
alignment between films and CT images can be used to quantify nodal dose differences from
independent ICBT insertions. Second, deformable image registration can be used to sum
normal tissue dose from EBRT and ICBT. Third, ray-tracing methods can be used to
determine interfractional anatomical variation margin requirements for proton therapy of
nodal boost.
5.2 SPECIFIC AIMS
5.2.1 Specific Aim 1
Specific Aim 1 was to quantify variations in pelvic nodal dose due to applicator
placement during a multi-fraction ICBT course. By analyzing differences in positive lymph
nodal dose contribution from independent ICBT fractions, we have demonstrated that the
mean dose to the nodes can differ by up to 1.9 Gy. However, only 20 percent of nodal dose
varied by greater than 1 Gy. Two tailed Spearman’s rho correlation tests between tandem
angle and length variations, applicator system location variations in the RL, AP, SI
directions, total magnitude of applicator system shift, and normalized nodal dose differences
from independent ICBT fractions were performed. Tandem angle and total system shifts
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were found to impact distal nodal dose differences while AP/PA and lateral shifts were found
to impact proximal nodal dose differences.
5.2.2 Specific Aim 2
The goal of Specific Aim 2 was to develop and validate deformable image
registration methods for the use of volumetric summation of bladder and rectum dose from
ICBT to an external beam planning CT image set. We have successfully developed a method
to improve DIR accuracy of bladder and rectum between EBRT and ICBT CT images while
creating a voxel-by-voxel method to validate our results. DIR of the bladder and rectum
between the EBRT and ICBT image sets were improved by creating a binary image from the
original CT images using contours delineated by radiation oncologists. Our novel validation
method uses population CT images to generate a pair of simulated CT images with known
deformations between them. Validations of our binary method for DIR of bladder and rectum
have shown mean deformation error for all voxels to be 4.6 mm and 5.6 mm, respectively.
5.2.3 Specific Aim 3
This aim was to calculate nodal boost planning margins needed for proton therapy to
account for interfractional anatomical variations. To determine the required margins, we used
a fast ray-tracing method to measure differences in WEPL at the target distal and proximal
edges. We used our method to evaluate interfractional anatomical variations in the common
iliac and external iliac nodal regions with varying beam angles. We have concluded that
beam angles are a major determinant of the margins necessary for patients undergoing proton
therapy. Beams passing through the bowel region, where gas content and weight loss may
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cause great anatomical variations, require much larger margins than beams entering from
other directions.
5.3 TRANSLATING FINDINGS TO THE CLINIC
The results from each one of the three aims can all be independently used to improve
current clinical practice. By quantifying the nodal dose variations from independent ICBT
fractions, radiation oncologists can refer to the results of Specific Aim 1 when deciding how
much extra dose, if necessary, to prescribe to account for the uncertainties in the second
ICBT fraction. Also, when conformal radiation therapy is used during external beams and
spatial total dose information for the bladder and rectum necessary for evaluation, method
developed in Specific Aim 2 can be used to volumetrically deform ICBT dose onto the
external beam CT image. Since we also devised a volumetric validation method for our DIR
algorithm and calculated the mean errors of DIR in the bladder and rectum, physicists and
radiation oncologists understand the limitations and accuracy of the results when evaluating
the summed dose.
For dose delivery to the positive nodes, Specific Aim 3 have determined the margins
required to ensure target coverage. The margins required to account for interfractional
anatomical variations can then be added in quadrature with currently used margins
accounting for other proton uncertainties. Since most patients only require a few fractions of
nodal boost, treatment with protons for a week should not cause any inconvenience to the
patient. Also, by using protons, we take advantage its physical properties and spare normal
tissues beyond the distal edge. For patients already experiencing normal tissue complexities
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from primary EBRT and ICBT, protons have the potential to spare tissue that would have
been impossible to avoid with photons.
5.4 THE END?
Although we have reached conclusive results in all three aims of the project, the
knowledge gained from this work will be passed on and be used for future projects. The
methodologies and tools developed in this project are universal and can be used in many
anatomical sites. Our deformable image registration validation method is extremely useful at
a time when dose accumulation using DIR has become much more accessible to the clinic. It
is robust and can be used on any treatment site and DIR algorithm. Unlike other validation
methods, it does not require intensive and time consuming landmark identification or
creating a phantom which might or might not represent the specific patient population and
deformation. Also, our method of determining interfractional anatomical variations in proton
therapy using ray-tracing method is not just limited to this project. As long as repeat CT
images are available for the population of interest, interfractional anatomical variations can
be quantified for any target and beam angle. In conclusion, the methods created and used in
this project is just as important as the results. My biggest wish is for future researchers to
take the methods used in this project and apply it to suit their own specific needs.
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